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Abstract: To address analytical detection needs, sensitive and selective assay 
methodologies are of great importance. Compared to simple buffer medium, a great 
challenge exists in detecting ultra-low levels of biomarkers in clinical matrices due to their 
inherent complexity and interferences posed by non-specific molecules. In addition, small 
molecules do not yield measurable assay signal changes compared to large biomolecules. 
My thesis research is focused on designing nano-biological interfaces to detect small and 
large molecules at low parts-per-billion and femto/picomolar concentrations in complex 
biofluids (serum and urine samples). Compared to harsh and tedious chemical 
carboxylation, non-covalent carboxylation of multiwalled carbon nanotubes by π-π 
stacking 1-pyrenebutyric acid retains the innate sp2 structure and electronic properties of 
the nanotubes and offers surface carboxyl groups for stable covalent amine coupling of a 
large amount of enzymes, thus improving the sensitivity of the assay. Chapter 2 
demonstrates the first pyrenyl carbon nanostructure modified enzymatic bioelectrode for 
amperometric detection of urine formaldehyde at clinically relevant parts-per-billion levels 
with selectivity and wide dynamic range. Subsequently, we explored the low dielectric 
permittivity and intrinsic plasmonics of graphene for the detection of serum glutamic acid 
decarboxylase autoantibody (GADA). Graphene-based electrochemical immunosensing 
approach is advantageous due to its additional applicability for surface plasmon based 
validation and binding strength analysis with surface immobilized GAD-65 antigens 
(Chapter 3). My thesis focused on the third class of biomarkers, microRNAs, which are 
small oligonucleotides with 21-25 bases. To develop the microRNA assay with quantitative 
characterization, surface plasmon resonance imaging (SPRi) coupled with quartz crystal 
microbalance (QCM) was designed (Chapter 4). Gold nanoparticles (Au NPs) were linked 
to the oligonucleotides to increase the detection sensitivity upon hybridization with the 
selective capture oligonucleotide immobilized on the sensor surface with minimal non-
specific signals. Often, cancer and other similar health disorders have been shown to be 
related to various types of biomarkers. Hence, in Chapter 5, we designed a multiplex assay 
platform for combined measurement of proteins and microRNAs. For this multiplex assay, 
we synthesized iron-gold bimetallic core/shell nanoparticles (Fe3O4@Au NPs) that 
displayed a greater plasmonic signal amplification than either Fe3O4 or Au NPs.  
. 
 
vi 
 
TABLE OF CONTENTS 
 
CHAPTER 1          PAGE 
 
ELECTROCHEMICAL AND SURFACE PLASMON BIOASSAYS FOR 
CIRCULATING BIOMARKERS ...........................................................................1 
 
1.1 Introduction ..............................................................................................................1 
1.2 Nanostructure-modified enzyme electrodes ............................................................3 
1.3 Pyrenyl carbon nanostructures for ultrasensitive measurements of formaldehyde in 
urine (Chapter 2) ......................................................................................................5 
 1.3.1 Approach and novelty .....................................................................................5 
 1.3.2 Outcomes and significance .............................................................................6 
1.4 Ultrasensitive electrochemical immunoassays ........................................................7 
1.5 Electrochemical and surface plasmon correlation of serum autoantibody 
immunoassay with binding insights: graphenyl vs. mercapto-monolayer surface 
(Chapter 3) ...............................................................................................................9 
 1.5.1 Approach and novelty .....................................................................................9 
 1.5.2 Outcomes and significance ...........................................................................10 
1.6 SPRi bioassays for protein and nucleotide biomarkers .........................................11 
1.7 Measuring ultra-low levels of nucleotide biomarkers using quartz crystal 
microbalance and SPR microarray imaging methods: a comparative analysis (Chapter 
4) ............................................................................................................................12 
 1.7.1 Approach and novelty ...................................................................................12 
 1.7.2 Outcomes and significance ...........................................................................13 
1.8 Multiplexed surface plasmon assay for serum proteins and micro-ribonucleic acids: 
signal amplification by bimetallic Fe3O4@Au nanoparticles (Chapter 5) .............14 
vii 
 
 1.8.1 Approach and novelty ...................................................................................14 
 1.8.2 Outcomes and significance ...........................................................................16 
1.9 Conclusions and future directions  .........................................................................16 
1.10 References ............................................................................................................18 
  
CHAPTER 2          PAGE 
 
PYRENYL CARBON NANOSTRUCTURES FOR ULTRASENSITIVE 
MEASUREMENTS OF FORMALDEHYDE IN URINE ....................................23 
 
2.1 Introduction ............................................................................................................23 
2.2 Experimental ..........................................................................................................25 
 2.2.1 Materials and chemicals ................................................................................25 
 2.2.2 Instrumentation .............................................................................................26 
 2.2.3 Surface modification of AuSPE ....................................................................27 
 2.2.4 Chronoamperometric detection of formaldehyde in urine samples ..............28 
2.3 Results and Discussion ..........................................................................................29 
 2.3.1 FTIR characterization of the modified electrodes ........................................29 
 2.3.2 Raman characterization of the nano-bioelectrode fabrication steps .............30 
 2.3.3 Electrochemical impedance spectroscopy characterization ..........................31 
 2.3.4 Amperometric response for the stirred vs flow injection analysis ................32 
 2.3.5 LC-MS confirmation of the presence of HCHO in the prepared urine samples by 
derivatization with DNPH......................................................................................37 
 2.3.6 Stability and selectivity of the electrode .......................................................38 
2.4 Conclusions ............................................................................................................43 
2.5 References  .............................................................................................................44 
 
CHAPTER 3          PAGE 
 
ELECTROCHEMICAL AND SURFACE PLASMON CORRELATION OF SERUM 
AUTOANTIBODY IMMUNOASSAY WITH BINDING INSIGHTS: 
GRAPHENYL VS. MERCAPTO-MONOLAYER SURFACE............................52 
viii 
 
3.1 Introduction ............................................................................................................52 
3.2 Experimental ..........................................................................................................55 
 3.2.1 Materials and chemicals ................................................................................55 
 3.2.2 Instrumentation .............................................................................................55 
 3.2.3 Fabrication of the electrochemical immunosensor .......................................56 
 3.2.4 Magnetic bead-protein A/G capturing of autoantibody from 10% human serum 
(MAG-protein A/G-GADA) ..................................................................................57 
 3.2.5 SPRi microarray modification ......................................................................58 
 3.2.6 Quantitation of GAD-65 on the immunoassay surface .................................59 
 3.2.7 Quantitation of surface carboxyl groups based on electroactive aminoferrocene 
functionalization of graphene-COOH or MPA monolayer surface on 8xSPEs .....59 
 3.2.8 Electrochemical measurements of serum GADA by an immunoassay ........60 
3.3 Results and Discussion ..........................................................................................60 
 3.3.1 Optimization of GAD-65 concentration on the immunosensor surface  ......60 
 3.3.2 Hydrodynamic size and zeta potential measurements ..................................61 
 3.3.3 Microscopic characterization of the graphene immunosensor ......................62 
 3.3.4 Spectroscopic characterization of the graphene immunosensor ...................63 
 3.3.5 Electrochemical impedance spectroscopy characterization of the immunosensor 
fabrication ..............................................................................................................64 
 3.3.6 Estimation of signal enhancement and reduction of non-specific signals by the 
MAG-protein A/G beads over the direct use of serum GADA solution................66 
 3.3.7 Serum GADA concentration dependent increase in charge-transfer resistance  
................................................................................................................................67 
 3.3.8 Comparison of SPR responses for graphene-COOH and MPA modified 
immunosensor and bimolecular kinetic analysis ...................................................68 
 3.3.9 Validation of the graphene-COOH and MPA modified serum GADA  .......71 
 3.3.10 Estimation of the relative surface carboxyl groups on graphene-COOH and 
MPA modified gold surfaces .................................................................................72 
 3.3.11 Application to T1D patient samples and validation by a commercial ELISA kit
................................................................................................................................76 
3.4 Conclusions ............................................................................................................77 
ix 
 
3.5 References  .............................................................................................................78 
 
CHAPTER 4          PAGE 
 
MEASURING ULTRA-LOW LEVELS OF NUCLEOTIDE BIOMARKERS USING 
QUARTZ CRYSTAL MICROBALANCE AND SPR MICROARRAY IMAGING 
METHODS: A COMPARATIVE ANALYSIS.....................................................82 
 
4.1 Introduction ............................................................................................................82 
4.2 Experimental ..........................................................................................................84 
 4.2.1 Materials and chemicals ................................................................................84 
 4.2.2 Instrumentation .............................................................................................85 
 4.2.3 AuNP-linked oligonucleotide preparation ....................................................86 
 4.2.4 Quartz crystal surface modification and detection........................................87 
 4.2.5 Modification of the SPR microarray surface and detection ..........................87 
4.3 Results and Discussion ..........................................................................................89 
 4.3.1 Spectroscopic analysis of AuNP-linked oligonucleotides ............................89 
 4.3.2 Assessment of target hybridization and signal amplification by the mass sensor
................................................................................................................................91 
 4.3.3 Pixel intensity changes in the SPR microarray in response to target or control 
nucleotide hybridization with the surface capture probe .......................................93 
 4.3.4 Comparison of QCM and SPRi methods ......................................................95 
 4.3.5 Assessment of selectivity ..............................................................................96 
4.4 Conclusions ..........................................................................................................100 
4.5 References  ...........................................................................................................101 
 
CHAPTER 5          PAGE 
 
MULTIPLEXED SURFACE PLASMON ASSAY FOR SERUM PROTEINS AND 
MICRO-RIBONUCLEIC ACIDS: SIGNAL AMPLIFICATION BY BIMETALLIC 
Fe3O4@Au NANOPARTICLES .........................................................................107 
 
x 
 
5.1 Introduction ..........................................................................................................107 
5.2 Experimental ........................................................................................................109 
 5.2.1 Materials and chemicals ..............................................................................109 
 5.2.2 Instrumentation ...........................................................................................111 
 5.2.3 Synthesis and characterization of Fe3O4@Au bimetallic nanoparticles .....112 
 5.2.4 Preparation of the covalent conjugates of Fe3O4@Au NPs with detection 
antibodies .............................................................................................................113 
 5.2.5 Preparation of the conjugates of Fe3O4@Au with detection DNA molecules   
..............................................................................................................................113 
 5.2.6 Preparation of the four-channel microarray and multiplexed analysis .......114 
5.3 Results and Discussion ........................................................................................116 
 5.3.1 Hydrodynamic size and zeta potential of Fe3O4@Au NPs and conjugates        
..............................................................................................................................116 
 5.3.2 Elemental composition of the Fe3O4@Au NPs...........................................118 
 5.3.3 Estimation of SPRi signal amplification by Fe3O4@Au NPs over Fe3O4 or Au 
NPs of similar sizes ..............................................................................................118 
 5.3.4 Microscopic characterization of the NPs and surface binding event of the 
conjugates made with detection probes ...............................................................119 
 5.3.5 Quantitation of capture and detection molecules used in the designed SPRi 
microarray for multiplexed detection of miRNAs and ILs ..................................120 
 5.3.6 Real-time analysis of serum biomarkers .....................................................121 
 5.3.7 Analysis of binding strength of protein and miRNA markers ....................123 
5.4 Conclusions ..........................................................................................................129 
5.5 References  ...........................................................................................................130 
 
CHAPTER 6          PAGE 
 
SUMMARY ...............................................................................................................134 
xi 
 
 
 
 
LIST OF TABLES 
 
CHAPTER 2 
 
TABLE           PAGE 
 
Table 1. Comparison of the present MWNT/PBA-FDH nano-bioelectrode with relevant 
reported studies. ................................................................................................................ 40 
 
CHAPTER 3 
 
TABLE                                                                                                                        PAGE 
 
Table 1. Hydrodynamic size and Zeta potential values of MAG-protein A/G and MAG-
protein A/G-GADA beads (five times diluted in PBS, pH 7.4), temperature 25 oC. ....... 62 
 
Table 2. Kinetic parameters for the MAG-protein A/G beads captured serum GADA 
binding onto a surface immobilized GAD-65 antigen. ..................................................... 71 
 
Table 3. Estimated electroactive amounts of aminoferrocene on graphene-COOH and 
MPA modified electrodes. The estimations were based on anodic peak area (Q in nC) or 
peak currents (Ip in nA) from cyclic voltammograms shown in Fig. 9. ............................ 75 
 
Table 4. A. Results from the analysis of patient samples (10% serum) on the designed 
graphene-COOH electrochemical immunosensor and ELISA (N = 3). B. Recovery data 
of the designed EIS immunoassay with the ELISA method for a patient serum sample 
spiked with GADA. .......................................................................................................... 76 
 
xii 
 
CHAPTER 4 
 
TABLE                                                                                                                        PAGE 
 
Table 1. Sequences of designed oligonucleotides. ............................................................ 84 
 
Table 2. Quantitation of oligonucleotides immobilized on the QCM or SPR gold surface 
and conjugated to AuNPs (N = 3 replicates). ................................................................... 90 
 
Table 3. Analysis of the target oligonucleotide in different percentages of serum samples 
(diluted in PBS, pH 7.4) using the QCM and SPR microarray......................................... 97 
 
Table 4. Summary of recent studies related to nucleic acid detection. ............................. 98 
 
CHAPTER 5 
 
TABLE                                                                                                                        PAGE 
 
Table 1. Sequences of the custom-designed DNA oligonucleotides employed in this 
study. (In the hairpin capture DNA, the sequences in italics (underlined) are 
complementarity to the target miRNA sequence, the sequences in bold are the hairpin 
forming sequence, and those highlighted in gray are complementary to the sequence of 
the bimetallic NPs attached detection DNA. The detection DNA partially hybridizes with 
the exposed region of the hairpin surface DNA when pre-hybridized with the miRNA 
marker) ............................................................................................................................ 110 
 
Table 2. The hydrodynamic diameters and ζ-potentials of Fe3O4@Au NPs and their 
conjugates with a detection antibody (shown here for IL-6 second antibody) or a 
detection DNA probe. ..................................................................................................... 117 
 
xiii 
 
Table 3. The quantitation of capture molecules immobilized on the microarray and 
detection molecules conjugated to the Fe3O4@Au NPs. ................................................ 121 
 
Table 4. Detection performance comparison of our method with other SPR methods . 126 
 
  
xiv 
 
 
 
 
 
LIST OF FIGURES 
 
           
CHAPTER 1 
 
FIGURE               PAGE 
 
Figure 1. Types of biomarkers and the categories they fall under according to their 
potential roles (according to FDA, NIH and JDRF Biomarker Working Group 
categorization)..................................................................................................................... 2 
 
Figure 2. A. Schematic of different assay strategies designed in this thesis to measure 
biomarkers in clinical matrices: (1) small molecules, (2) antigens, (3) antibodies and (4) 
microRNAs. B. Various electrochemical and surface plasmon imaging-based detection 
strategies were utilized. ....................................................................................................... 3 
 
Figure 3. Pyrenyl-carbon nanostructure-modified disposable electrode for urine 
formaldehyde detection. ...................................................................................................... 6 
 
Figure 4. Immunosensor containing Graphene-COOH and MPA monolayers for serum 
GADA measurement and binding kinetic determination. ................................................. 10 
 
Figure 5. The QCM and SPRi sensors for selective detection of oligonucleotides of 
miRNA-21 mimic (Target) from a sequence containing five mismatches (Control) with 
AuNPs-based signal amplification. ................................................................................... 14 
 
xv 
 
 
Figure 6. Bimetallic Fe3O4@Au core/shell nanoparticles enhanced multiplexed SPRi 
bioassay to measure four serum cancer biomarkers. ........................................................ 15 
 
CHAPTER 2  
 
FIGURE                                                                                                                       PAGE 
 
Figure 1. Representation of the crystal structure of FDH from Pseudomonas aeruginosa 
(PDB 4JLW). The surface lysine (Lys) residues available for covalent attachment to 
surface carboxylic acid groups of PBA and MWNT are highlighted in red. .................... 27 
 
Figure 2. (A) Schematic of the microfluidics system used in this study. (B) Fabrication 
steps of the AuSPEs with FDH and the reaction sequence for catalyzing HCHO and 
detection by flow injection or stirred solution amperometry. ........................................... 28 
 
Figure 3. FTIR spectra of AuSPE coated with (a) carboxylated MWNTs, (b) after PBA 
stacking, and (c) after covalent immobilization of FDH .................................................. 30 
 
Figure 4. Raman spectra of AuSPEs coated with (a) Carboxylated MWNTs, (b) after 
PBA stacking, and (c) after covalent immobilization of FDH.......................................... 30 
 
Figure 5. Faradaic impedance spectroscopic measurements of Rct values in an aqueous 
solution containing 0.1 M KCl and 10 mM of Fe(CN)63-/4- for stepwise modification of 
(a) AuSPE (1792 Ω), (b) after dry-coating of MWNT (154 Ω), (c) after pi-pi stacking of 
PBA (67 Ω), and (d) after covalent immobilization of FDH (410 Ω). Experimental 
conditions: 0.2 V vs Ag/AgCl, amplitude 10 mV, and frequency range 0.1-100 kHz. .... 32 
 
Figure 6. Amperometric responses (after subtraction of signals for control urine sample 
with no spiked HCHO) of flow injection analysis of 1 ppm HCHO at various dilutions of 
xvi 
 
 
urine samples with PBS (pH 7.4) containing 5 mM NAD+ and 1 mM Q delivered a flow 
rate of 100 µL min–1 at an applied potential of + 0.35 V at 23 oC. ................................... 33 
 
Figure 7. (A) Stirred solution method: (a) Amperometric responses of the 
AuSPE/MWNT/PBA-FDH bioelectrode for various concentrations of HCHO in 10-times 
diluted urine in PBS, pH 7.4, containing 5 mM NAD+ and 1 mM Q at an applied potential 
of + 0.35 V at 23 oC and a constant stirring of solution using a magnetic stirrer at 150 
rpm. Inset shows the enlarged view for lower HCHO concentrations. (b) Michaelis-
Menten fit of the designed bioelectrode in oxidizing HCHO. (B) Flow injection analysis: 
(a) Amperometric responses for the AuSPE/MWNT/PBA enzyme bioelectrode upon 
injection of various concentrations of HCHO at a flow rate of 100 µL min–1. Inset shows 
the enlarged view for lower HCHO concentrations. (b) The corresponding Michaelis-
Menten fit of the experimental data. ................................................................................. 35 
 
Figure 8. Selectivity of the designed AuSPE/MWNT/PBA-FDH bioelectrode for HCHO 
over other similar analytes in stirred solutions. Current signals for 5 ppm of analytes (x-
axis) in 10-times diluted urine solutions in PBS are shown. ............................................ 36 
 
Figure 9. (A) LC-MS analysis of the presence of HCHO (5 ppm) in the prepared urine 
samples (10-times diluted) by DNPH derivatization method. Separation of (a) DNPH 
derivatized urine sample containing HCHO (5 ppm), (b) diluted urine sample with only 
DNPH, (c) diluted urine sample alone, and (d) standard DNPH-HCHO derivative (20 
ppm). (B) MS analysis showing the 209 Da peak for the formed DNPH-HCHO derivative 
in the urine sample. ........................................................................................................... 38 
 
Figure 10. Film stability assessment of the designed AuSPE/MWNT/ PBA-FDH 
bioelectrode for 40 h using electrochemical non-faradaic impedance spectroscopy at an 
applied frequency of 5 Hz in PBS, pH 7.4, room temperature (23 oC). ........................... 39 
 
 
xvii 
 
 
CHAPTER 3 
 
FIGURE                                                                                                                       PAGE 
 
Figure 1. Design of graphenyl  and mercapto monolayer based immunosensors for 
biosensing and binding kinetics analysis. Three electrode system in the 8xSPE array: 
gold working electrode (WE) and counter electrode (CE), pseudo Ag-reference electrode 
(RE). .................................................................................................................................. 53 
 
Figure 2. Rct values for increasing solution concentration of GAD-65 (in PBS solution) 
used for immobilization onto the carbodiimide activated graphene-COOH/gold surface, 
and followed by the binding of a constant concentration of 10% serum GADA (4 ng mL-
1) captured onto MAG-protein A/G beads. ....................................................................... 61 
 
Figure 3. SEM images of A. rough AuSPE surface, B. after dry coating of an aqueous 
suspension of graphene-COOH, C. after covalent attachment of GAD-65 antigen and 
surface blocking with 1% BSA, and D. after the binding of GADA spiked in 10% human 
serum (0.05 ng mL-1) and captured onto MAG-protein A/G beads. ................................. 63 
 
Figure 4. FTIR spectra of a. rough gold 8xSPE, b. after dry-coating with graphene-
COOH, c. after EDC/NHS activation, d. after GAD-65 immobilization, and e. after the 
binding of 5 ng mL-1 concentration of 10% serum GADA captured by the MAG-protein 
A/G beads.......................................................................................................................... 64 
 
Figure 5. Faradaic impedance spectroscopic measurements in an aqueous solution 
containing 0.1 M KCl and 10 mM each of Fe(CN)6
3-/4- mixture: (a) AuSPE (3310 ± 101 
Ω), (b) after dry-coating of graphene-COOH (1054 ± 154 Ω), (c) after covalently 
attaching GAD-65 by the carbodiimide coupling chemistry (2108 ± 67 Ω), (d) after 
blocking the free surface with 1% BSA (4190 ± 410 Ω), and (e) after the binding of 
serum GADA (0.04 ng mL-1) captured onto the MAG-protein A/G beads (9290 ± 580 Ω). 
xviii 
 
 
Experimental conditions: 0.2 V vs Ag/AgCl, amplitude 10 mV, and frequency range 0.1 - 
100 kHz. ............................................................................................................................ 65 
 
Figure 6. A. Rct values for the BSA blocked, graphene-COOH coated gold surface 
immobilized with GAD-65 upon the binding of MAG-protein A/G beads alone (1.25 mg 
mL-1), GADA (2 ng mL
-1) spiked in 10% serum in PBS (pH 7.4), and serum GADA (2 ng 
mL-1) captured onto the MAG-protein A/G beads. B. Reduced non-specific background 
signals for MAG-protein A/G added toGADA unspiked serum compared to the GADA 
unspiked free serum solution. ........................................................................................... 66 
 
Figure 7. Nyquist plots obtained from the Faradaic impedance measurements in an 
aqueous solution containing 0.1 M KCl and 10 mM each of Fe(CN)6
3-/Fe(CN)6
4- for 
various concentrations of surface bound serum GADA immunoassembly : A. Graphene-
COOH (0.02, 0.05, 0.1, 0.25, 0.5, 0.75, 1, and 2 ng mL-1) and B. MPA (0.02, 0.05, 0.1, 
0.25, 0.5, and 0.8 ng mL-1) modified immunosensors.C and D represent the dynamic 
range of respective response plots for Rct changes with concentration of GADA for N = 3 
replicates. Ten percent serum not spiked with any GADA but treated with the MAG-
protein A/G beads was used as the control sample, and its Rct value was subtracted from 
each of the GADA spiked serum sample responses. (Experimental conditions:      0.2 V 
vs pseudo-Ag reference electrode, amplitude 10 mV, and frequency range 0.1–100 kHz.)
........................................................................................................................................... 68 
 
Figure 8. Simulated (red) and real-time SPR sensograms (black) for different 
concentrations (a to c) of 10% serum GADA, 0.05, 0.10, and 0.50 ng mL-1, captured with 
MAG-protein A/G beads and bound onto GAD-65 immobilized sensor surfaces modified 
with A. graphene-COOH and B. MPA. ............................................................................ 70 
 
Figure 9. DPV responses showing the decrease in currents for 10% serum containing 
GADA concentrations of a. 0.0, b. 0.02, c. 0.05, d. 0.1, e. 0.2, f. 0.5, and g. 0.75 ng mL-1 
captured with MAG-protein A/G beads, and upon binding with the surface GAD-65 
antigen on A. graphene-COOH and B. MPA modified immunosensors. Experimental 
xix 
 
 
conditions: aqueous mixture containing 0.1 M KCl and 10 mM each of Fe(CN)6
3-
/Fe(CN)6
4- with potential scanned from + 0.6 to - 0.1 V vs a pseudo-Ag reference 
electrode. C and D represent the linear DPV responses of the immunosensors modified 
with graphene-COOH and MPA, respectively. ................................................................ 72 
 
Figure 10. Background subtracted CVs of A. graphene-COOH, B. MPA modified gold 
electrodes with a. covalently attached, and b. adsorbed films of aminoferrocene in argon 
purged PBS buffer, pH 7.4, 23 °C. The scan rate was 0.1 V s−1. ...................................... 73 
 
Figure 11. Background subtracted scan rate dependent CVs of the covalently attached 
aminoferrocene on A. graphene-COOH and C. MPA modified Au 8xSPEs and the 
respective plots of peak current vs scan rate (B and D). The scan rate inner to outer: 0.075 
- 1.2 V s-1 at 23 oC, in PBS, pH 7.4................................................................................... 74 
 
CHAPTER 4 
 
FIGURE                                                                                                                       PAGE 
 
Figure 1. Fabrication procedure of the SPR microarray chip for selective detection of the 
target miRNA-21 mimic (T) from the control (C) oligonucleotide sequence by 
hybridization in a dual channel SPRi system. ................................................................... 88 
 
Figure 2. UV-visible spectra of (a) AuNPs before conjugation to oligonucleotides and 
AuNPs linked to (b) target or (c) control oligonucleotide present in 0.1 M NaCl/ 0.1 M 
sodium phosphate buffer (pH 7.4). ................................................................................... 89 
 
Figure 3. SEM images of (A) a bare gold spot of the SPR microarray before modification 
and (B) the gold spot self-assembled with the thiol-activated surface capture probe. (C) 
Higher magnification image of (B). .................................................................................. 91 
 
xx 
 
 
Figure 4. A. Mass changes for the gold-coated quartz crystals modified with the surface 
capture probe upon addition of increasing concentration (in pM) of (a) target 
oligonucleotide captured onto AuNPs, (b) target oligonucleotide not linked to AuNPs, (c) 
control oligonucleotide linked to AuNPs, and (d) the control not linked to AuNPs. B. 
Mass changes shown for (a) control and (b) target oligonucleotides (0.5 pM) with or 
without linking to AuNPs. Data shown are mean ± standard deviations represented by 
error bars for N = 3 replicates. Relative standard deviations (RSDs) for the control were 
17% with no AuNPs and 22% with AuNPs linkage. The RSDs for the target were 11% 
(no AuNPs) and 7% (with AuNPs). .................................................................................. 92 
 
Figure 5. Real-time SPR response (average of eight array spots) for the binding of 0.5 pM 
of (a) target or (b) control oligonucleotide linked with AuNPs onto the surface 
immobilized capture probes at a flow rate of 50 μL/min. Sample injection and buffer 
wash points are labeled. .................................................................................................... 93 
 
Figure 6. Representations of SPRi responses: the 3D representation (left) and the line 
profile (right) that depicts the SPR pixel intensities for various concentrations of target 
and control nucleotides. The spot labeled as (a) is the bare gold surface treated with 5 
mM MHOH and that of (b) are the test spots containing the immobilized capture probes. 
(A)-b: control oligonucleotide of (i) 0.1, (ii) 0.5, (iii) 1, (iv) 10, (v) 30, and (vi) 50 pM 
concentrations conjugated with AuNPs; and (B)-b: target oligonucleotide of 
concentrations similar to those of the control allowed to bind with the surface capture 
probe……………………………………………………………………………………94 
 
Figure 7. Double logarithmic calibration plots of (A) QCM response (control response is 
subtracted) and (B) SPRi response (control response is subtracted) upon hybridization of 
various concentrations of the AuNP-conjugated target oligonucleotide with the surface 
capture probe. (mean ± standard deviation for three replicates). ...................................... 96 
 
 
xxi 
 
 
CHAPTER 5 
  
FIGURE                                                                                                                       PAGE 
 
Figure 1. Schematic illustration of the synthesis of Fe3O4@Au bimetallic NPs using the 
reaction mixture consisting of 1. HAuCl4.3H2O, 2. Fe3O4 NPs, and 3. sodium citrate. . 112 
 
Figure 2. A. The experimental set-up for multiplexed SPRi analysis using a four-channel 
flow injection system. B. The SPRi chip was modified with capture probes (CAb: capture 
antibodies or CDNA: capture DNA) and the analytes were assayed as follows: Two lanes 
(4 spots each) of the SPRi microarray were self-assembled with a monolayer of MPA. 
The remaining two lanes were self-assembled with thiol-activated hairpin capture DNAs 
of miRNA-21 and miRNA-155 (4 spots each) followed by blocking the free surface with 
MHOH. The IL-6 and IL-8 capture antibodies were covalently attached to the -COOH 
activated MPA surface (4 spots each) followed by blocking of the free surface with 1% 
BSA. Various concentrations of the protein and miRNA markers were spiked in 10% 
human serum and allowed to bind their respective capture molecules on the chip using 
the designated individual flow channels. The signal amplification step of the bioassay 
was subsequently followed by introducing the respective detection molecules (DAb: 
detection antibodies or DDNA: detection DNA) conjugated to Fe3O4@Au NPs yielding 
detection DNA-Fe3O4@Au or detection antibody-Fe3O4@Au NPs. .............................. 115 
 
Figure 3. The SPRi responses of A. 100 nm Fe3O4 NPs, B. 75 nm Fe3O4@Au NPs, C. 100 
nm Au NPs, and D. 105 nm Fe3O4@Au NPs adsorbed onto 0.1 mg mL
-1 PEI coated gold 
surface. (a) Schematic and experimental 3D images of SPR pixel intensity, (b) only the 
PEI adsorbed gold surface. The corresponding line profiles, and difference images (in 
grey) are shown on the right. .......................................................................................... 119 
 
Figure 4. TEM image of A. Fe3O4@Au NPs. SEM images of B. bare Au surface of the 
microarray, C. IL-6 capture antibody/IL-6/Fe3O4@Au NP-IL-6 detection antibody 
xxii 
 
 
assembly, and D. miRNA-155 capture DNA/miRNA-155/Fe3O4@Au NP-miRNA-155 
detection DNA assembly. ............................................................................................... 120 
 
Figure 5. SPRi responses for a multiplexed assay by the 4-channel flow injection analysis 
A. Real-time pixel intensity changes for 10% serum spiked with a. IL-8 (10 nM), b. IL-6 
(10 nM), c. miRNA-21 (0.25 nM), and d. miRNA-155 (0.25 nM). I. Represents the 
introduction of the 10% serum spiked with the markers to the capture probe coated 
microarray and II. represents the introduction of the detection probes conjugated to 
Fe3O4@Au NPs. B. Final difference image of the test spots after detection of protein and 
miRNA markers in a single microarray. C and D. Corresponding 3-D representation and 
line profile, respectively.................................................................................................. 122 
 
Figure 6. SPRi calibration plots for A. protein markers (IL-6 and IL-8) and B. miRNA 
markers (miRNA-21 and miRNA-155) in 10% human serum. (N = 3 replicates). ........ 123 
 
Figure 7. Representative plots of the relative surface coverage (θ) as a function of the 
concertation of A. IL-6, B. IL-8, C. miRNA-21, and D. miRNA-155. The solid line 
represents the Langmuir isotherm fit to the data. All measurements were made in 
triplicates. ........................................................................................................................ 125 
 
 
 
1 
 
 
CHAPTER 1   
 
 
ELECTROCHEMICAL AND SURFACE PLASMON BIOASSAYS FOR CIRCULATING 
BIOMARKERS  
1.1 Introduction  
Designing highly sensitive and selective bioassay methodologies is imperative to overcome the 
analytical challenge of not only determining the ultra-low concentrations of biomarkers that are 
present in complex matrices (blood, serum, urine, saliva, etc.), but also to assess slight variations 
occurring during physiological abnormalities. Biomarkers are specific molecules whose 
concentration levels in blood, tissues and other organs/body fluids can be related to a normal or 
abnormal process, or a condition or disease.1 Assaying clinically relevant biomarkers present in 
complex body fluids can enable early diagnosis and monitoring response to treatments as well as 
recurrence. An outline of various types of biomarkers and their applicability with relevance to 
different stages of disease depending on their biological function is shown in Figure 1.  
Even though many sensitive techniques including chromatography-mass spectrometry, radioactive 
assays, and molecular biology techniques are known, high cost, complexity of assay steps for 
clinical samples, limitation of assaying in a multiplex format, no feature of real-time binding 
analysis (useful for sensitive biosensor development by facilitating conditions to attain strong 
interactions), and the need of expensive labels for the detection steps.   
Electrochemical techniques have received immense attention because they are simple to operate, 
easy to fabricate, produce rapid detection signals, cost effective, and can be used as miniaturized 
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platforms for onsite measurements.2,3 Surface plasmon resonance (SPR) has been predominantly 
used as a sensitive technique that could measure real-time ligand-receptor binding events and the 
kinetics associated with them.4,5 Combining electrochemical and SPR techniques can provide 
complementing information useful for any new bioanalytical assay development.  
Figure 1. Types of biomarkers and the categories they fall under according to their potential roles 
(according to FDA, NIH and JDRF Biomarker Working Group categorization) 
Both electrochemical and SPR biosensors carry or consist of the same basic elements as of a general 
biosensor. A bio-recognition molecule, specific for the target analyte, is immobilized on the surface 
and a transducer producing the desired signal change when the target analyte binds to the surface 
receptor.6 These biosensors face the general limitations of suffering from non-specific signals, 
orientation issues of surface receptors affecting the extent of analyte binding sites, and long-term 
stability. To mitigate some of these drawbacks, various nanomaterials and surface bioconjugation 
chemistries to improve the detection sensitivity, orientation, and stability.  In addition to addressing 
these common pitfalls, we have initiated a research direction focusing on binding constant based 
biosensor optimization to increase detection sensitivity and thus lower the detection limits.  
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This chapter provides an overview of recent trends in electrochemical and surface plasmon 
resonance (SPR) bioassays for small and large biomolecule markers. A summary of contribution 
from my thesis research on the design of various bioassay strategies is presented (Figure 2). 
Furthermore, the use of appropriate surface recognition elements and incorporation of different 
nanomaterial-based approaches for signal amplification and non-specific signal reduction are 
discussed.  
Figure 2. A. Schematic of different assay strategies designed in this thesis to measure biomarkers 
in clinical matrices: (1) small molecules, (2) antigens, (3) antibodies and (4) microRNAs. B. 
Various electrochemical and surface plasmon imaging-based detection strategies were utilized.   
1.2 Nanostructure-modified enzyme electrodes 
Enzyme-based electrochemical sensors are a sub-class of biosensors that are built by immobilizing 
substrate-specific enzymes on the working electrode surface. Electrochemical signals are produced 
as a result of the enzyme catalyzing the small molecule of interest. As the most critical component 
of the sensor, enzymes can be stably immobilized on the sensor by use of various nanomaterials 
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and nanocomposites as a type to improve sensitivity.7 The analyte small molecule can be selectively 
probed as the substrate for a specific enzyme irrespective of the matrix it is available.  
Thulium oxide nanorods (n-Tm2O3) electrophoretically-deposited onto indium-tin oxide glass 
electrode for total cholesterol detection in clinical samples through a dual enzyme functionalization 
(with cholesterol esterase (ChEt) and cholesterol oxidase (ChOx)) has been reported.8 Tm2O3 
improved the electroactive area, diffusion of substrates to the enzymes and electron transfer kinetics 
that resulted in a broad linear range for cholesterol detection. A poly(phenylenediamine) 
biomembrane with a molecular sieving feature was developed to amperometrically determine the 
glutamate uptake and accumulation in the nerve terminals at millimolar levels.9 The biomembrane 
resulted storage stability up to 11 days at 4 oC with a loss of 25% of initial activity. Without the 
biomembrane, the sensor showed a large cross-reactivity with ascorbic acid, which was not clearly 
addressed. A reagentless amperometric biosensor was developed by Hughes et al. following a 
layer-by-layer process by alternatively depositing chitosan and multiwalled carbon nanotubes 
(MWNTs) on Meldola’s Blue screen printed carbon electrodes.10 The layers encapsulated the 
glutamate dehydrogenase enzyme and the cofactor nicotinamide adenine dinucleotide (NAD+).  
The sensor had the capacity to determine glutamate concentrations in food and serum samples with 
less than 10% coefficient of variation among five replicates. Reagentless enzymatic amperometric 
biosensor eliminates the requirement for additional redox probes during the detection step, which 
decreases the assay duration. However, the effectiveness of layer-by-layer modification on the 
reproducibility and shelf-life of the sensor needs to be further investigated. 
As another mechanistic approach to entrap large quantities of enzymes, Reuillard and coworkers 
developed an amperometric glucose sensor, which was efficiently built by polypyrrolic bipyridine 
bis(phenantrolinequinone) Ru(II) complex ([RuII(PhQ)2(bpy-pyrrole)]) formed by 
eletropolymerization on a MWNT-modified glassy carbon electrode (GCE).11 This one-step 
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development of [RuII(PhQ)2(bpy-pyrrole)] nano-polymer composite was compared to a layer-by-
layer deposition of [RuII(PhQ)2(bpy-pyrrole)] and poly[12-(pyrrol-1-yl) dodecyl]triethylamnonium 
tetrafluoroborate. Even though the layer-by-layer method entrapped more enzymes, the sensor 
performance was poor due to additional steric effects imposed on cofactor permeation towards the 
electrocatalytic layer. Recently, a nanostructured enzyme-less glucose sensor was developed on a 
glassy carbon electrode modified with a nanohybrid mixture of MWNTs/Au NPs/iron oxide 
nanoparticles (Fe2O3 NPs).12 The aggregation of Fe2O3 NPs above an optimum concentration 
hindered the electron transfer through MWNTs, which in turn lowered the sensitivity of the sensor 
by 2-folds.  
1.3 Pyrenyl carbon nanostructures for ultrasensitive measurements of formaldehyde in urine 
(Chapter 2) 
1.3.1 Approach and novelty 
We recently demonstrated a novel approach for enzyme-selective detection of formaldehyde in 
urine using a flow injection amperometric sensor (Figure 3).13 An amperometric nano-bioelectrode 
design that uniquely combined 1-pyrenebutyric acid (PBA) units pi-pi stacked with carboxylated 
MWNTs on the surface of gold screen printed electrodes was used for covalent attachment of NAD+ 
dependent formaldehyde dehydrogenase (FDH). Based on our prior reports, the large number of     
–COOH groups made available by MWNT/PBA modification promotes greater covalent 
attachment of surface biomolecules,14-16 and is convenient to perform compared to the tedious 
chemical functionalization of MWNTs that could potentially alter their electronic properties. FDH 
is a selective enzyme towards formaldehyde oxidation, which minimized non-specific 
interferences. Fourier transform infrared, Raman, and electrochemical impedance spectroscopic 
characterizations confirmed the successful design of the FDH bioelectrode. An electron transfer 
mediator-based efficient approach using quinone compound (Q: 1, 2-naphthaquinone-4-sulfonic 
6 
 
 
acid sodium salt) was followed to obtain electrochemical signals that are proportional to 
formaldehyde concentration.   
1.3.2 Outcomes and significance  
The non-covalent functionalization of MWNTs with PBA offered a larger amount of carboxyl 
functionalities, which in turn was useful to covalently immobilize a large amount of FDH on the 
electrode surface to increase the sensitivity. Flow injection analysis provided greater affinity for 
formaldehyde (apparent KM 9.6 ± 1.2 ppm) when compared with stirred solution method (apparent 
KM 19.9 ± 4.6 ppm). The flow injection analysis demonstrated a lower detection limit and wider 
dynamic range than the stirred solution method in 10-times diluted urine matrix. This could be 
likely due to the better diffusion of reactants to products on the electrode surface by use of a 
continuous sample flow. The sensor offered a superior selectivity over other homologous aldehydes 
except for a moderate cross-reaction with acetaldehyde (~25%) possibly due to its partial affinity 
to the enzyme’s binding pocket.17  
 
 
 
 
 
 
Figure 3. Pyrenyl-carbon nanostructure-modified disposable electrode for urine formaldehyde 
detection. 
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Our results demonstrated that pyrenyl carbon nanostructure-based FDH bioelectrode design 
represent a novel and simple for enzyme-selective electrochemical quantitation of small 30 Da 
formaldehyde. Broader applicability of our approach to other small-molecule markers is feasible 
depending on the design of appropriate marker-specific enzyme systems or receptor molecules. 
1.4 Ultrasensitive electrochemical immunoassays  
Nano-modified electrochemical immunoassays have received a sound attention in past few years 
in the rapidly growing biomarker sensing applications.18 A typical electrochemical immunoassay 
consists of a reporter molecule which is responsible to produce the corresponding electrical signal 
upon the target molecule is bound to the specific receptor. Dutta and coworkers reported a sandwich 
type immunosensor to determine the low femtogram per milliliter concentration of Plasmodium 
falciparum histidine-rich protein-2 in plasma.19 A highly sensitive redox-cycling approach was 
followed by using methylene blue tagged second antibodies to produce chronocoulometric signals 
after going through an endergonic reaction with Ru(NH3)63+ and a highly exergonic reaction with 
tris (2-carboxyethyl)phosphine (TCEP). This eliminated the requirement for expensive enzymatic 
labels and demonstrated high specificity, excellent reproducibility and good stability. Another 
highly sensitive immunosensing platform, which measured femtogram per milliliter levels of a 
food-borne pathogen marker Enteropathogenic coli (E. coli) antigen, a unique and highly sensitive 
redox-cycling detection mechanism was followed.20 The outersphere reaction-philic/innersphere 
reaction-philic transfer from Ru(NH3)63+/2+/immunosensor to ferritin-H2O2 redox system resulted in 
a higher signal to noise ratio than a traditional ferritin labeled immunoassay. While this redox-
cycling scheme offered similar sensitivity to the methylene blue-TCEP redox system, it has the 
advantage of having negligible interference from dissolved oxygen in the electro-reduction process.   
A major number of immunosensors developed recently have been focused on determining 
biomarkers related to various cancer conditions. In this effort, an enzyme cascade reaction was 
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employed to measure serum concentration of a tumor marker neuron-specific enolase (NSE) 
utilizing a multifunctional conductive hydrogel containing polypyrrole-polythionine-Au NPs with 
glucose oxidase due to its ease of synthesis through a one-pot reaction, large specific surface area 
offered and high conductivity and signal to noise ratio.21 However, the inherent mechanical 
weakness and non-adherence to certain surfaces could limit the use of hydrogels in biosensors.  
Carvajal and coworkers reported a low-cost disposable inkjet-printed electrode array (< $0.25) to 
detect clinically relevant levels of a breast cancer biomarker human epidermal growth factor 
receptor 2 (HER-2).22 Even though a relatively faster assay time (15 min) were achieved by an 
integrated flow of HER-2, biotinylated antibody, and polymerized horseradish peroxide labels via 
a microfluidic system, this study did not demonstrate any evidence that mimics the real-use of 
determining HER-2 in human serum. A direct immunoassay was built on disposable graphene 
screen-printed electrode modified with branched polyethylenimine to detect serum glial fibrillary 
acidic protein, a central nervous system injury biomarker.23 The simple adsorption of PEI provided 
enriched amounts of primary and secondary amine functional groups for the immobilization of a 
large amount of capture antibody via a Schiff base reaction using glutaraldehyde. This was 
advantageous over the creation of self-assembled monolayers, electropolymerization, plasma-
polymerization, and salts with functional groups that have complex protocols with several time-
consuming functionalization steps. Nonetheless, adsorbed layers of polymers are prone to 
desorption due to strong mechanical stress applied on the sensor, which in turn, could hamper the 
sensitivity.  
Recently, significant efforts have been put by scientists in regard to measurements of insulin levels 
in clinical matrices to draw plausible conclusions on diabetic conditions. Krishnan and coworkers 
reported electrochemical immunosensor designs that employed MWNTs non-covalently 
functionalized with 1-pyrenebutyric acid by pi-pi stacking to increase the surface carboxyl 
9 
 
 
functional groups, which in turn improved the amount of immobilized anti-insulin second 
antibodies to detect low picomolar levels of insulin in diluted human serum.24,25 Magnetic 
nanoparticles covalently linked with anti-insulin capture antibodies were used to conveniently 
capture the serum insulin, which reduced the possible non-specific signals and increased the 
sensitivity of the detection signals.  
1.5 Electrochemical and surface plasmon correlation of serum autoantibody immunoassay 
with binding insights: graphenyl vs. mercapto-monolayer surface (Chapter 3) 
1.5.1 Approach and novelty 
Conventionally, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), 
chemiluminescent immunoarray (CLIA), and electrochemiluminescence assays have been used by 
the researchers for clinical diagnosis of type 1 diabetes (T1D). These analytical techniques are 
tedious to perform, lacked quality check parameters and required expensive labels. We developed 
an immunosensor design on carboxylated graphene (graphene-COOH) or self-assembled 
monolayer of mercaptopropionic acid (MPA)-modified screen printed eight electrode array 
(8xAuSPE). We used an inexpensive ferricyanide reagent to accomplish the simple electrochemical 
detection of serum glutamic acid decarboxylase autoantibody (GADA) (Figure 4).26 According to 
prior studies, both graphene27-29 and mercapto monolayers30-32 have been widely used to effectively 
functionalize immunoassay surfaces in order to immobilize biomolecules.  
Graphene is an excellent alternative to surface chemistries that cannot be directly used on surface 
plasmon resonance imager (SPRi) array surface due to optical limitations (e.g., carbon nanotubes). 
With its conductive 2D nanostructure and intrinsic plasmonic activity, graphene can be used for 
both electrochemical and SPR surface modification. Herein, we used SPRi as a complementary 
method to the electrochemical methods to evaluate binding constants (KD) associated with GADA 
interaction with its antigen, GAD-65. A unique approach was followed to isolate the GAD antibody 
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from serum samples by protein A/G modified magnetic beads to minimize non-specific 
interactions. This comparative analysis of the graphene-COOH and MPA provided useful 
fundamental information regarding immunosensing of serum GADA and binding insights on 
GADA-GAD65 interaction, which are discussed in detail in Chapter 3.   
Figure 4. Immunosensor containing Graphene-COOH and MPA monolayers for serum GADA 
measurement and binding kinetic determination. 
1.5.2 Outcomes and significance  
The graphene surface offered a lower detection limit with a wider dynamic range compared to the 
MPA monolayer surface, and exhibited a good statistical correlation with the commercial ELISA 
method. The lower KD value for the graphene-COOH modified surface suggests that graphene 
provides a stronger GADA-GAD-65 binding interaction, which in turn relates to a more sensitive 
platform. Through electrochemical quantitation, it was found that the number of surface carboxyl 
groups available for covalent interaction was about 9-times greater in graphene-COOH than the 
mercapto monolayer surface. The larger number of carboxyl groups on graphene provided room to 
immobilize a greater amount of GAD-65 antigen combined with the reduction of non-specific 
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binding occurring on the immunosensor surface, which improved sensitivity. The combined 
sensing and binding assessment studies provided useful insights for broader applications on 
developing reliable, and better throughput clinical immunosensors for biomarker based diagnostic 
assays. 
1.6 SPRi bioassays for protein and nucleotide biomarkers   
SPRi is one of the many SPR techniques that have been established, and can operate as a high-
throughput and label-free technique for the analysis of variety of molecular interactions. Typical 
SPRi works based on Kretschmann configuration in which a monochromatic light source is used 
to generate surface plasmons across an array consisting of a thin plasmonic metal film in contact 
with a dielectric medium. A CCD camera is used to acquire digital images to monitor the intensity 
of light reflected as a result of refractive index changes occurring at the metal-dielectric interface.33 
To increase the sensitivity of the SPRi-based detection, various surface nanomaterial assemblies, 
enzymatic amplification, self-assembly of proteins and DNAs and plasmonic nanoparticle coupling 
have been followed.34  
Sankiewicz and coworkers developed an SPR assay to measure fibronectin in blood samples of 
children with thermal injuries.35  The assay used a simple immunoassay strategy by immobilizing 
fibronectin specific monoclonal antibodies on a mercapto monolayer formed on the gold SPRi array 
and did not require any tags, dyes or specialized reagents. However, the assay sensitivity was only 
moderate with the detection limit of 1.5 ng mL-1, limiting its use to measure biomarkers of clinical 
relevance in ultralow picogram or femtogram per milliliter levels. In another work, an orthogonal 
signal amplification strategy was followed by coupling a miRNA-initiated surficial cyclic DNA-
DNA hybridization reaction with a DNA-initiated upward cyclic polymerization reaction.36 In this 
way the sensitivity was improved to sub-femtomolar concentration detection. However, this 
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method has an intrinsic limitation while applying to a multiplexing platform as it would require the 
design of multiple DNA oligonucleotides if a panel of miRNA markers are to be tested.  
Multiplexing combined with a microfluidic format allows a rapid and efficient analysis of multiple 
biomarkers, minimizing the need for multiple experiments. Hendriks and coworkers recently 
developed a multiplexed SPRi detection cascade using neutravidin and gold nanoparticles to 
measure IL-1β, IL-6, IFN-γ, and TNF-α in femtogram and picogram per milliliter range.37 Though 
the enhancement cascade improved the sensitivity by about 40,000 times in a buffer medium, when 
applied to complex fluids, large non-specific interactions of the surface receptor antibodies led to 
a 1000-fold decrease in the overall sensitivity of the assay. In another recent report, a competitive 
multiplexed SPRi immunoassay was developed to measure insulin, glucagon and somatostatin in 
buffer medium.38 The indirect assay was useful to overcome the limitation arising from small 
molecule detection signals by SPRi, which would often result in no measurable signal changes at 
ultralow concentrations. The drawback in such assay is that it has detection limits in the nanomolar 
range and has not achieved measurements of markers under study in any complex matrix. 
SPRi can become a vital complementary technique to electrochemical methods by enabling real-
time binding insights on various types of molecules associated with appropriate receptor molecules 
immobilized on the array surface. Also, SPRi can be used as a better throughput platform at 
instances where the electrochemical methods cannot measure more than a single sample at a time. 
1.7 Measuring ultra-low levels of nucleotide biomarkers using quartz crystal microbalance 
and SPR microarray imaging methods: a comparative analysis (Chapter 4) 
1.7.1 Approach and novelty 
Circulating serum nucleotide biomarkers are useful indicators for early diagnosis of various deadly 
diseases. In particular, miRNA-21 (miRNA-21) has been found to be relevant to infectious 
diseases, such as viral and bacterial infections, as well as non-infectious diseases such as 
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cardiovascular disorders and cancer. A combination of mass sensor and SPRi methods that utilize 
the same assay chemistry on gold are useful detection with quantitative insights. In this work, we 
compared detection performances of a quartz crystal microbalance (QCM), which is a mass sensor, 
with that of a SPRi microarray for an oligonucleotide mimic of the miRNA-21 biomarker (Figure 
5).39  
A surface immobilized capture oligonucleotide probe was designed and custom synthesized to 
hybridize with the target oligonucleotide (i.e., the miRNA-21 mimic) to facilitate selective 
detection. The direct method of forming a self-assembled monolayer of capture probes on the gold 
surface eliminated the need for additional surface functionalization steps. Gold nanoparticles (Au 
NPs, 50 nm) were conjugated with the target oligonucleotide to increase the detection sensitivity 
by adding more mass on the surface on the QCM sensor as well as enhancing the plasmonic signals 
in an SPRi microarray. To assess the selectivity of the capture probes towards the target 
oligonucleotide, an Au NP-linked control oligonucleotide containing five base-pair mismatches to 
the target oligonucleotide was used. Additionally, sample recovery studies were performed to 
analyze the serum matrix effect. 
1.7.2 Outcomes and significance  
We achieved detection limits of 28 and 47 fM for the target oligonucleotide by the QCM and SPRi 
microarray approaches, respectively. Although the QCM was more sensitive and had a lower 
detection limit, it was throughput limited. The microarray approach offered better throughput for 
analysis of up to 16 samples, thus the analysis of sample and controls in a single experiment using 
a dual channel microfluidic system was possible. 
The combination of QCM with SPRi can be practically significant as it is useful for quantitative 
characterization and assay step optimization before applying for a high-throughput platform. We 
confirmed that the designed assay was selective for the target oligonucleotide and did not show 
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signals for the control base mismatch oligonucleotide. According to the sample recovery studies (> 
90%), there was a negligible interference from the serum matrix up to 25% in buffer. QCM studies 
revealed the effectiveness of conjugating Au NPs with the target oligonucleotides to increase the 
sensitivity of the detection signal by about three times. The strategy discussed above opens up an 
avenue in developing a SPRi-based multiplexed platform to measure multiple biomarkers in 
clinical matrices. 
 
 
 
 
 
 
 
Figure 5. The QCM and SPRi sensors for selective detection of oligonucleotides of miRNA-21 
mimic (Target) from a sequence containing five mismatches (Control) with AuNPs-based signal 
amplification.  
1.8 Multiplexed surface plasmon assay for serum proteins and micro-ribonucleic acids: 
signal amplification by bimetallic Fe3O4@Au nanoparticles (Chapter 5) 
1.8.1 Approach and Novelty  
Highly expressed circulating protein and miRNA markers play a significant role in indicating 
critical health conditions and measuring them together in one assay platform offers the advantages 
of increasing the prediction rates and reduction of false positive diagnoses. We recently expanded 
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our existing dual channel SPRi microfluidic system into a four-channel system to develop a 
multiplexed assay to simultaneously measure four circulating cancer biomarkers (two proteins: IL-
6 and IL-8, and two miRNAs: miRNA-21 and miRNA-155) in human serum (Figure 6).40 The SPRi 
microarray uniquely employed citrate-stabilized bimetallic iron-gold bimetallic core/shell 
nanoparticles (Fe3O4@Au NPs) as signal amplification labels covalently linked with secondary 
detection molecules. Various bimetallic NPs have been built by combining the beneficial properties 
of two metals and have been employed in biosensing applications.41 In particular, the Fe3O4@Au 
NPs offered the distinctive benefits of easy conjugation and magnetic separation of desired 
compounds for subsequent detection in the assay.42 The plasmonic properties of the gold shell were 
useful for amplifying the SPR detection signals.43 SPRi allowed the real-time monitoring of the 
binding events of the protein and miRNA biomarkers to their surface receptors. Multiplexing was 
useful to directly assay the two protein markers by a sandwich immunoassay and the two serum 
miRNA markers by a double hybridization assay in a serum sample.  
Figure 6. Bimetallic Fe3O4@Au core/shell nanoparticles enhanced multiplexed SPRi bioassay to 
measure four serum cancer biomarkers.   
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1.8.2 Outcomes and significance  
The Fe3O4@Au (105 nm) NPs exhibited 13-times higher plasmon signal intensities than that of 
only Fe3O4 NPs (100 nm) and 6-times greater signals than Au only NPs (100 nm). The magnetic 
feature of Fe3O4@Au NPs was useful for convenient separation of the detection probes that were 
covalently linked (binding efficiency > 70%). The plasmon enhancing features of Fe3O4@Au NPs 
aided in amplifying the SPRi signal output for analyte markers while minimizing the non-specific 
signals arising from the serum matrix. The detection limits achieved for the markers were in the 
pM to sub-pM concentration range.  
In 10% serum, the dynamic range of detection for the proteins was from pM to nM (~104 orders of 
magnitude), and for the miRNAs, the dynamic range was from fM to nM (~106 orders of 
magnitude). The binding constants determined from Langmuir-type binding kinetics was from µM 
to nM range, which provided evidence of strong affinities between the analyte biomarkers and their 
receptor molecules on the designed sensor surface. This feature is vital in understanding the degree 
of interaction of the chosen receptors with the target analytes in bioassays. Further, this SPRi array 
has the potential to be adopted as a tool for analysis of other biomarkers present in clinical samples. 
1.9 Conclusions and future directions 
In summary, this chapter mainly attempted on discussing various electrochemical and SPRi assay 
methodologies developed recently to measure biomarkers in complex matrices, and the 
contributions of the research presented in this dissertation have added new knowledge on 
combining electrochemical and SPRi methods to determine quality check parameters in devising 
clinical biosensors with high sensitivity and selectivity. Up to date, scientists have been working 
tirelessly to advance the field of sensors by developing many impressive electrochemical and SPR 
based biosensor technologies and have disseminated their findings through a plethora of research 
publications. However, so far, only a handful of electrochemical biosensors have reached the 
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commercialization stage. A similar trend can be observed with the reported superior SPR diagnostic 
assays for biomarker measurement that have still not made it to a clinical setting. Of course, it 
should be noted that significant research efforts are needed to increase the efficiency, robustness 
and reproducibility of bioassay designs, and applicability for a large number of samples in order to 
translate them from laboratory bench into practically implementable methods.  
With the increasing population suffering from numerous types of deadly diseases, advanced 
biosensor technologies are critical for early-diagnosis and prognosis, in order to commence suitable 
therapeutic regimes in a timely manner. In particular, the advantages of electrochemical sensor 
technologies and nanotechnology can be combined to develop potential miniaturized devices for 
personalized continuous biomarker measurements. Future developments in embroidered 
electrochemical sensors, contact-lens based sensors, sweat sensors and edible biosensors would 
shift the diagnostic world to a new paradigm. Similarly, besides the biosensing feature, the ability 
to determine binding insights of various biomolecule interactions by SPRi can be utilized in 
selecting appropriate surface designs and biorecognition elements for a wide range of biosensors. 
In parallel to electrochemical techniques, SPR is expected to transform to a user friendly technology 
by appropriate tuning of the portability and interfacial sensing features. The outlook for 
electrochemical and SPR research certainly remains positive and many breakthroughs are realizable 
with continuous explorations.   
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CHAPTER 2   
 
 
PYRENYL CARBON NANOSTRUCTURES FOR ULTRASENSITIVE MEASUREMENTS 
OF FORMALDEHYDE IN URINE 
2.1 Introduction 
Biomarkers are molecular indicators that play a crucial role in the diagnosis, prognosis, and 
theranostics of diseases such as cancer.1 As a result, bioanalytical methods that allow sensitive and 
selective measurements of biomarkers are significant for clinical applications and therapeutics 
development. In view of diagnostic challenges, the molecular size of a biomarker present in 
complex body fluid matrices inversely affects the detection sensitivity. This is because small 
molecules do not yield measurable assay signal changes compared to large biomolecules. 
Additionally, dilution of samples to minimize clinical matrix effects can further lower the 
biomarker concentration and its detection. False-positive signals, tedious extraction procedures of 
analytes from the matrices, simplicity of the assay and detection protocol, and selectivity are other 
related problems.  
Despite the issues described, nanotechnology-based optical and electrochemical methods have 
allowed detection of large proteins, receptors, antibodies, DNA, and RNA biomarkers at clinically 
relevant pM to aM concentrations in body fluids.2 However, development of such analytical assays 
with simplicity, selectivity, sensitivity, and low-cost for detecting small-molecule markers of 
Adapted from G. Premaratne, S. Farias, and S. Krishnan, Pyrenyl carbon nanostructures for ultrasensitive 
measurements of formaldehyde in urine, Analytica Chimica Acta, 2017, 970, 23 –29 with permission from 
Elsevier. 
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cancer and other diseases non-invasively remains to be a significant challenge. In particular, 
bioanalytical methods for detection of ultra-low ppb levels of formaldehyde (HCHO) in a complex 
clinical matrix (e.g., plasma, serum, urine) suffer by interferences from non-analyte components 
present in the matrix (non-specific signals), poor detection capability, and issues of enzyme 
instability and loss of enzyme activity. Furthermore, non-invasive detection of biomarker levels is 
advantageous for routine diagnosis of these diseases at an early stage as it eliminates painful 
invasive procedures (e.g., biopsy, bronchoscopy), which are known to cause tissue and organ 
damage.3 Moreover, we can eliminate minimally invasive procedures, such as drawing of blood 
from patients for analysis.4 In this study, we demonstrate for the first time the design of pyrenyl 
carbon nanostructure modified electrodes for formaldehyde dehydrogenase (FDH) immobilization 
and electrochemical quantitation of HCHO in a urine matrix with a 6 ppb detection limit. 
Aldehydes, including HCHO, have received considerable attention as a key class of volatile organic 
compound markers that exhibit toxic effects in humans, and are suggested to be relevant for cancer 
and neural diseases.5-8 Many techniques have been developed to detect HCHO, including 
spectrophotometric,9 electrochemical,10,11 optical,12 electronic,13 and colorimetric14 methods. 
Sensitive detection of urine HCHO by chromatography-mass spectrometry methods is known. 
However, these methods involve expensive instrumentation, and time consuming laborious sample 
preparation, measurement, and analysis steps.5 In contrast, electrochemical methods are 
straightforward and cost effective.15,16 In particular, electrochemical enzymatic amperometric 
biosensors offer the advantages of direct and quick detection of analytes with simplicity. By 
appropriate design of surface strategies, high sensitivity, robustness, and excellent reproducibility 
can be attained. 
FDH (~ 170 kDa), an enzyme of the oxidoreductase family,17,18 is a homotetrameric enzyme 
containing 398 amino acids per subunit. Ali et al. developed a biosensor made from NAD+ and 
glutathione-dependent recombinant FDH immobilized on the surface of a Si/SiO2/Si3N4 structure.11 
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A mediator-based amperometric biosensor was constructed on disks of woven graphite gauze 
coated with NAD+ and glutathione-independent FDH from Hyphomicrobium zavarzinii strain ZV 
58.19 Demkiv et al. modified platinized graphite electrodes with NAD+ and glutathione-dependent 
FDH isolated from a genetically engineered strain H. polymorpha. In that study, electron transfer 
between the enzyme and the electrode was established using low molecular weight redox mediators 
or positively charged cathodic electrodeposition paints modified with Os-bis-N,N-(2,2'-bipyridyl)-
chloride ([Os(bpy)2Cl]).20 FDH from Pseudomonas sp. immobilized on mesoporous silica 
materials21 and multiwalled carbon nanotube-modified screen printed electrodes22 for HCHO 
detection in buffer solution have been developed. 
Herein, we report for the first-time 1-pyrenebutyric acid (PBA) pi-pi stacked with carboxylated 
multiwalled carbon nanotubes (MWNTs) on the surface of the gold screen printed electrodes 
(AuSPEs) for covalent FDH immobilization offering highly sensitive and selective ultra-low 
detection HCHO concentration in a 10-times buffer diluted urine. We combined here the –COOH 
groups of MWNTs with the non-covalently attached PBA because this combination approach, 
discovered by us recently, offered 3-fold improved sensitivity for a serum insulin immunosensor 
compared to the use of only carboxylated MWNTs.23 HCHO was quantitated using a quinone 
compound (Q: 1, 2-naphthaquinone-4-sulfonic acid sodium salt) as an electron transfer mediator to 
obtain electrochemical signals in proportion to HCHO concentration. To our knowledge, this is the 
first report of a pyrenyl carbon nanostructure based enzymatic bioelectrode for urine HCHO 
quantitation. 
2.2 Experimental  
2.2.1 Materials and chemicals 
Gold screen printed electrodes (AuSPEs) with a three-electrode cell configuration integrated on a 
ceramic substrate (Model: 250 BT, 4 mm diameter Au working electrode, Pt counter electrode, and 
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Ag pseudo reference electrode) were purchased from DropSens Inc. (Spain). Multiwalled 
carboxylic acid functionalized carbon nanotubes (MWNTs, > 8% carboxylic acid functionalized, 
avg. diam. 9.5 nm, length 1.5 µm), β-nicotinamide adenine dinucleotide sodium salt (NAD+), FDH 
from Pseudomonas sp., PBA, 1,2-naphthaquinone-4-sulfonic acid sodium salt (Q), HCHO solution 
(36.5 – 38% in water), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC),       
N-hydroxysuccinimide (NHS), and formaldehyde-2,4-dinitrophenylhydrazone analytical standard 
(HCHO-DNPH) for liquid chromatography were purchased from Sigma and were used as received. 
Vivaspin 6 ultrafiltration cartridges (molecular weight cut off: 3 kDa, GE Healthcare, Little 
Chalfont, Buckinghamshire, UK) were used for filtration of urine. All aqueous reagents were 
prepared in deionized water (DI H2O) using a Milli-DI water purification system (Millipore Ltd., 
Billerica, Massachusetts, USA). All other chemicals were high purity analytical grade. 
2.2.2 Instrumentation 
Amperometric measurements were performed at room temperature (23 oC) using a CHI 6017E 
electrochemical workstation coupled to a faraday cage and a picoamp booster (Austin, TX, USA).  
The flow-cell was connected to a syringe pump system (New Era Pump Systems Inc., NY, USA) 
and a sample injector valve (Rheodyne model 9725i PEEK injector, IDEX Health & Science LLC, 
CA, USA). The sample loop volume was 200 μL. Spectroscopic characterizations of the 
bioelectrode fabrication steps were carried out using Fourier transform infrared spectroscopy 
(FTIR, Thermo Scientific Nicolet iS50) in the attenuated total reflectance (ATR) mode. The 
bioelectrodes were placed directly on the ATR diamond crystal and 32 scans were taken and 
averaged to obtain a good signal-to-noise ratio. In addition, Raman spectroscopy (Nicolet NXR 
FT-Raman module, Nd:YVO4 laser, 1064 nm, 0.2 W, resolution 4 cm-1) and  electrochemical 
impedance spectroscopy (Interface 1000 potentiostat/galvanostat/ZRA, Gamry instruments, 
Warminster, PA) were used for the characterization of the designed bioelectrode. Liquid 
chromatography-mass spectrometry (LC-MS) with an electrospray ionization source (Shimadzu 
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LCMS-2010EV) was used for identification of HCHO-DNPH derivative, methanal 2,4-
dinitrophenylhydrazone. 
2.2.3 Surface modification of AuSPE  
Briefly, on the surface of disposable AuSPEs, 5 µL dispersions of 2 mg mL–1 MWNTs in 
dimethylformamide (DMF) were added to cover the entire AuSPE surface and allowed to dry at 
room temperature. The electrodes were washed well with deionized H2O and dried under nitrogen 
prior to adding 3 µL of 3 mg mL–1 PBA solution in DMF. The electrodes were kept in a cold and 
moist environment for 1 h to allow the formation of strong pi-pi interactions between MWNTs and 
PBA. The electrodes then were washed well with deionized H2O and dried under nitrogen.  
Figure 1. Representation of the crystal structure 
of FDH from Pseudomonas aeruginosa (PDB 
4JLW). The surface lysine (Lys) residues 
available for covalent attachment to surface 
carboxylic acid groups of PBA and MWNT are 
highlighted in red. 
 
 
FDH enzyme was covalently linked via its free surface lysine residues (PDB: 4JLW, Figure 1) to 
the –COOH terminal groups of both the MWNT and PBA assembly by the established 
carbodiimide chemistry.24 To carry out this reaction, MWNT/PBA-modified AuSPEs were treated 
with 5 µL solution of a freshly prepared mixture containing 0.35 M EDC and 0.1 M NHS for 15 
min to activate the surface carboxylic acid groups of MWNTs and PBA into lysine (Lys) amine 
reactive N-succinimidyl esters. The electrodes were then washed with deionized H2O to remove 
unreacted reagents and subsequently treated with 5 µL of 200 µg/mL FDH solution prepared in 
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phosphate buffered saline (PBS) and incubated for 1 h to obtain covalently linked FDH films. The 
prepared electrodes were used immediately for measuring HCHO in urine. 
2.2.4 Chronoamperometric detection of formaldehyde in urine samples  
Urine samples were collected from a healthy male adult volunteer in a 50 mL sterile polyethylene 
vial. Samples were then immediately vortexed and divided into 10 mL aliquots and stored at -20 
oC for up to 30 days to avoid any storage loss. Before use, the frozen samples were thawed at 
room temperature. Prior to spiking with formaldehyde, a 6 mL aliquot of the urine sample was 
subjected to centrifugal filtration using Vivaspin-6 cartridges at a speed of 4000 rpm for 30 min at 
room temperature.25 Filtered urine samples were diluted 10-times in PBS. Various concentrations 
of formaldehyde were spiked in the 10-times diluted urine and were used for analysis.  
Figure 2. (A) Schematic of the microfluidics system used in this study. (B) Fabrication steps of the 
AuSPEs with FDH and the reaction sequence for catalyzing HCHO and detection by flow injection 
or stirred solution amperometry. 
FDH-immobilized AuSPE/MWNT/PBA electrodes were attached to an in-house designed flow cell 
that was connected to a syringe pump and a sample injector (Figure 2A). The running buffer was 
made up of PBS containing 5 mM NAD+ and 1 mM Q. Various concentrations of HCHO prepared 
in 10-times diluted urine in PBS were injected via a manual injector valve onto the bioelectrode 
surface. Real-time measurements of the oxidation currents of QH2 formed from NADH as a result 
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of FDH catalyzed HCHO oxidation were performed at an applied constant potential of + 0.35 V 
(Figure 2B).21,26 The current versus HCHO concentration was plotted and the resulting curve was 
fit by the Michaelis-Menten non-linear regression equation available with the K-graph software 
used. 
2.3 Results and Discussion  
2.3.1  FTIR characterization of the modified electrodes 
Figure 3 shows the baseline corrected FTIR-ATR results for the modified bioelectrode surface that 
confirmed the covalent immobilization of FDH onto the –COOH groups of AuSPE/MWNT/PBA 
electrodes. A strong vibrational peak at 1714 cm–1 indicated the presence of carbonyl stretching 
from the –COOH groups of MWNTs. Pi-pi stacking of PBA with MWNTs red shifted the C=O 
stretching vibration to 1698 cm–1, which has been attributed to the partial electron transfer from 
PBA to MWNT resulting in a relatively weaker C-C bond strength in the MWNT/PBA complex 
than the MWNT alone.27 Additionally, a broad peak at 3136 cm–1 for the O-H stretching was 
observed.28 Following covalent FDH attachment via coupling of Lys amines with surface 
carbodiimide activated (EDC/NHS) -COOH groups of PBA and MWNTs forming amide bonds, 
typical amide-I and amide-II bands from the peptide backbone of FDH were observed at 1683 and 
1603 cm–1, respectively.29 The disappearance of the prior O-H stretching and appearance of a new 
broad band at 3472 cm–1 arising from N-H stretching of FDH indicated amide bond formation and 
thus the enzyme immobilization. Furthermore, it is possible that a partial non-covalent adsorption 
of the FDH onto the MWNT/PBA surface cannot be ruled out. Despite this, based on the observed 
FTIR spectral changes of the surface carboxylic acids the covalent FDH attachment is evident. 
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Figure 3. FTIR spectra of AuSPE coated 
with (a) carboxylated MWNTs, (b) after 
PBA stacking, and (c) after covalent 
immobilization of FDH 
 
 
 
 
2.3.2 Raman characterization of the nano-bioelectrode fabrication steps 
Figure 4 represents the Raman spectra of AuSPE coated with MWNT, after pi-pi stacking with 
PBA, and subsequent covalent immobilization of FDH by Lys amine-carboxylic acid coupling 
chemistry using EDC/NHS reagents. The Raman spectrum of carboxylated MWNT-coated 
AuSPEs showed the characteristics D, G, and G′ bands at 1316, 1594, and 2614 cm-1, 
respectively.30,31 Decrease in frequency of these bands to 1304, 1585, and 2605 cm-1, respectively, 
as a result of pi-pi stacking of the PBA molecules was observed.32,33  
Figure 4. Raman spectra of AuSPEs 
coated with (a) Carboxylated 
MWNTs, (b) after PBA stacking, and 
(c) after covalent immobilization of 
FDH. 
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Another band at 2902 cm-1 can be attributed to the aromatic C-H groups arising from PBA 
molecules. A further shift in the G band and the appearance of new peaks at 1634 and 3310 cm-1 
indicated the presence of amide groups confirming the covalent attachment of FDH onto 
MWNT/PBA assembly on AuSPEs.  
2.3.3 Electrochemical impedance spectroscopy characterization  
Figure 5 represents the Nyquist plots corresponding to the faradaic impedance measurements for 
each step of the FDH bioelectrode construction in an aqueous solution containing 0.1 M KCl and 
a mixture of 10 mM of each potassium ferricyanide and potassium ferrocyanide redox probe 
[Fe(CN)63-/4-]. The Randles equivalent circuit model was used to fit the experimental impedance 
spectra to estimate the charge transfer resistance (Rct) similar to our prior report.34 MWNT/PBA 
modification of AuSPE surface decreased the Rct and thus made the surface more conductive (inset 
of Figure 5 for clarity). This is suitable for facilitating interfacial charge transport. Subsequent 
covalent attachment of the FDH enzyme onto the EDC/NHS activated surface –COOH groups of 
PBA and MWNT increased the Rct value, as would be expected for non-conductive enzyme 
molecules.  
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Figure 5. Faradaic impedance spectroscopic measurements of Rct values in an aqueous solution 
containing 0.1 M KCl and 10 mM of Fe(CN)63-/4- for stepwise modification of (a) AuSPE (1792 
Ω), (b) after dry-coating of MWNT (154 Ω), (c) after pi-pi stacking of PBA (67 Ω), and (d) after 
covalent immobilization of FDH (410 Ω). Experimental conditions: 0.2 V vs Ag/AgCl, amplitude 
10 mV, and frequency range 0.1-100 kHz. 
2.3.4 Amperometric response for the stirred vs flow injection analysis 
The enzyme fabricated SPEs were assessed for HCHO oxidation in a 10-times diluted urine matrix. 
The ability of the enzyme to function well in the urine matrix was very important, and thus adequate 
NAD+ cofactor (5 mM) was supplied. Ten times dilution of urine provided the optimum 
performance of the FDH bioelectrode with minimal non-specific signals in the working potential 
region as discussed below. FDH-catalyzed detection of HCHO was performed according to the 
reaction sequence shown in Figure 2B. Q was used as the electron transfer mediator to transfer 
electrons to the electrode from NADH formed in solution as a result of the FDH-catalyzed HCHO 
oxidation.21 This in turn regenerates NAD+ to receive subsequent protons upon HCHO oxidation. 
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Upon dilution of the urine matrix, an increase in the amperometric current was observed (Figure 6, 
tested using 1 ppm of HCHO for method optimization). This could be attributed to the reduction in 
high salt concentration and other interfering agents for the optimum performance of the sensor 
and/or the FDH enzyme.35 Diluting the urine samples more than ten times did not significantly 
increase the amperometric response. Hence, ten times dilution of the urine was selected for further 
studies.  
 
 
 
 
 
 
Figure 6. Amperometric responses (after subtraction of signals for control urine sample with no 
spiked HCHO) of flow injection analysis of 1 ppm HCHO at various dilutions of urine samples 
with PBS (pH 7.4) containing 5 mM NAD+ and 1 mM Q delivered a flow rate of 100 µL min–1 at 
an applied potential of + 0.35 V at 23 oC. 
Figure 7A-a shows the increase in currents of the bioelectrode in stirred solutions containing 
various concentrations of HCHO from ppb to ppm levels in 10-times diluted urine matrix at an 
optimum solution stirring rate of 150 rpm. Linearity of the currents vs. concentration of HCHO 
was observed between 100 ppb and 16 ppm (initial range in Fig. 7A-b), which is a wide dynamic 
range useful for clinical assay of such markers. A deviation from the linearity was observed at 
higher concentrations of HCHO (i.e., > 16 ppm) and followed typical electrochemical Michaelis-
Menten enzyme kinetics (Fig. 7A-b).36 The estimated apparent Michaelis-Menten constant (KMapp) 
using KaleidaGraph software (version 4.1) was 19.9 ± 4.6 ppm. The limit of detection (LOD) (the 
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signal at three times the standard deviation of the mean of the HCHO unspiked control urine 
sample37) of the described stirred solution-based HCHO detection was 73 ppb.                                        
To examine improvements on the detection sensitivity of the stirred solution method by facilitating 
better mass transport of HCHO and other assay reagents, we used flow injection analysis.38  
The cofactor and electron transfer mediator containing solution mixture (5 mM NAD+ and 1 mM 
Q in PBS, pH 7.4) was delivered at an optimum flow rate of 100 µL min–1 onto the FDH 
bioelectrode surface using a syringe pump. Various concentrations of HCHO spiked in 10-times 
diluted urine in PBS (pH 7.4) then were injected via a manual injection valve, and the resulting 
oxidation currents were measured (Figure 7B-a).   
The sensitivity of HCHO detection was only moderately enhanced (by two times) in the flow 
injection method compared to the stirred solution (calculated from the slopes of the initial linear 
range in Fig. 7A-b and 7B-b). A possible reason could be that the HCHO and mediators used are 
small molecules. As a result the mass transport by convection (stirring vs fluid flow) does not seem 
to be greatly different in view of sensitivity (i.e., the slope of response plots covering the linear 
range of HCHO concentrations). Nevertheless, the flow injection analysis significantly decreased 
the LOD to 6 ppb, which is 12-fold smaller than the stirred-solution method. This is likely because 
diffusion of reactants to products (cofactor, urine matrix, and mediator reaching the electrode and 
the product diffusing away) becomes much more prominent at the lowest concentration 
corresponding to the LOD. As a result, the flow injection method for the designed bioelectrode 
seems to be better than the stirred-solution analysis in facilitating effective electronic 
communication of the low levels of urine HCHO with the surface of the AuSPE/MWNT/PBA 
enzyme electrode. 
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Figure 7. (A) Stirred solution method: (a) Amperometric responses of the AuSPE/MWNT/PBA-
FDH bioelectrode for various concentrations of HCHO in 10-times diluted urine in PBS, pH 7.4, 
containing 5 mM NAD+ and 1 mM Q at an applied potential of + 0.35 V at 23 oC and a constant 
stirring of solution using a magnetic stirrer at 150 rpm. Inset shows the enlarged view for lower 
HCHO concentrations. (b) Michaelis-Menten fit of the designed bioelectrode in oxidizing HCHO. 
(B) Flow injection analysis: (a) Amperometric responses for the AuSPE/MWNT/PBA enzyme 
bioelectrode upon injection of various concentrations of HCHO at a flow rate of 100 µL min–1. 
Inset shows the enlarged view for lower HCHO concentrations. (b) The corresponding Michaelis-
Menten fit of the experimental data. 
Reported studies based on chromatography and mass spectrometry methods identified increased 
levels of HCHO present in the urine samples of patients with dementia and bladder cancer 
conditions compared to healthy individuals. Thus, the obtained LOD of the FDH bioelectrode for 
measuring HCHO in urine meets the reported clinically relevant range [e.g., bladder cancer (> 85 
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ppb),39 dementia (> 5.8 ppm),8a and early stages of cognitive impairments in older adults (> 330 
ppb)8b]. The lower LOD illustrates the advantages of flow injection analysis in improving analyte 
mass transport and minimizing noise levels, resulting in an enhanced signal-to-noise ratio and thus 
an improved detection limit. The linear dynamic range of our flow analysis for HCHO in 10-times 
diluted urine was from 10 ppb to 10 ppm. 
The relationship between current signal and HCHO concentration was fit by the Michaelis-Menten 
non-linear regression curve (Figure 7A-b and 7B-b) using KaleidaGraph software (version 4.1). 
The estimated KMapp of flow injection method was 9.6 ± 1.2 ppm,  which is better than the stirred-
solution method and likely due to enhanced substrate mass transport facilitating kinetically faster 
steady state conditions in the flow system. The observed difference between the affinity constants 
was calculated to be significant at 95% confidence level. Previously reported KM values of HCHO 
solution bioassays were 5.4 ppm for FDH from genetically engineered H. polymorpha,20 7.5–8.7 
ppm for a homologous enzyme from Candida boidinii,40 6.3 ppm for FDH from H. polymorpha,41 
and 12.9 ppm for FDH from Pichia pastoris.42 Results indicate that the KMapp values obtained in 
the present work are comparable with the reported bioassays. 
Figure 8. Selectivity of the designed 
AuSPE/MWNT/PBA-FDH bioelectrode 
for HCHO over other similar analytes in 
stirred solutions. Current signals for 5 
ppm of analytes (x-axis) in 10-times 
diluted urine solutions in PBS are shown. 
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The presented FDH bioelectrode design offers sensitivity, ultra-low clinically useful LOD, and 
simplicity, but it is also essential to meet selectivity criteria for clinical diagnosis of small-molecule 
disease markers. Figure 8 depicts the current signals for HCHO with two immediate aldehyde 
homologues and with acetone and two types of alcohol. The current responses confirm the high 
selectivity for HCHO, with ~ 25% cross-reactivity for acetaldehyde (CH3CHO) and negligible 
cross-reactivity for propanaldehyde, acetone, methanol, and ethanol. The moderate cross-reactivity 
for acetaldehyde suggests that the substrate binding pocket of the FDH enzyme has a slight affinity 
for this immediate homologue of HCHO that does not vary significantly in size. 
2.3.5 LC-MS confirmation of the presence of HCHO in the prepared urine samples by 
derivatization with DNPH  
The presence of spiked HCHO in the urine samples was independently verified by LC-MS (Figure 
9).43-45 In brief, to a vial containing 5 mL of HCHO (5 ppm) in 10-times diluted urine,  2 mL of 1 
mg mL-1 DNPH and 0.2 mL of 5 N H3PO4 were added and the solution was thoroughly mixed. The 
solution was allowed to stand for 30 min for DNPH derivatization of HCHO forming a Schiff base 
(methanal 2,4-dinitrophenylhydrazone derivative: HCHO-DNPH)). The samples were then filtered 
using a 0.22 µm PTFE syringe membrane filter before analysis by LC-MS.  A Premier C18, 3 µ 
100 x 4.6 mm column (Schimadzu) was used with a mobile phase composition of acetonitrile:water 
mixture (60:40) and a flow rate of 0.3 mL min-1. The LC peaks were detected using a photodiode 
array detector operating in the wavelength range of 200-800 nm with a selected wavelength of 354 
nm that corresponds to the HCHO-DNPH derivative. Mass spectra were recorded in the m/z range 
of 100 to 350 Da using an electrospray ionization operated in negative ion mode. As shown in 
Figure 9-A(a), the HCHO-DNPH derivative appears around 5.8 min in agreement with the peak of 
the derivative standard [Figure 9-A(d)]. The peak at 4.5 min corresponds to the underivatized 
DNPH in the sample [Figure 9-A(a and b)]. It can be noted that the blank urine sample does not 
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interfere with the derivative detection [Figure 9-A(c)]. The 209 m/z corresponds to the HCHO-
DNPH derivative that is in agreement with the prior report in literature (Figure 9-B).45 
Figure 9. (A) LC-MS analysis of the presence of HCHO (5 ppm) in the prepared urine samples 
(10-times diluted) by DNPH derivatization method. Separation of (a) DNPH derivatized urine 
sample containing HCHO (5 ppm), (b) diluted urine sample with only DNPH, (c) diluted urine 
sample alone, and (d) standard DNPH-HCHO derivative (20 ppm). (B) MS analysis showing the 
209 Da peak for the formed DNPH-HCHO derivative in the urine sample. 
2.3.6 Stability and selectivity of the electrode  
The fabricated FDH bioelectrodes were tested for film stability in PBS (pH 7.4 at 23 oC) for 40 h 
by non-faradaic impedance spectroscopy at an applied constant frequency of 5 Hz (Figure 10).46 A 
stable impedance magnitude of 232 Ω was noted for more than 40 h. It is worth mentioning that 
AuSPEs are intended to be for disposable use and hence the observed stability upon continuous 
soaking of the modified, FDH attached SPE surface in a buffer solution is reasonably good. 
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Figure 10. Film stability assessment 
of the designed AuSPE/MWNT/ 
PBA-FDH bioelectrode for 40 h 
using electrochemical non-faradaic 
impedance spectroscopy at an 
applied frequency of 5 Hz in PBS, 
pH 7.4, room temperature (23 oC). 
 
 
 
Excluding the MWNT/PBA surface modification of AuSPEs, the bioelectrode design only required 
one step for FDH immobilization and subsequent detection and quantitation of HCHO in 10-times 
diluted urine. The various sample matrices used in the literature for HCHO and the reported linear 
dynamic range, detection limit, sensitivity, and bioelectrode stability are presented in Table 1. This 
comparison shows better performance of the pyrenyl-cabon nanostructure bioelectrode than simple 
buffer solution-based HCHO quantitation methods. 
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Table 1. Comparison of the present MWNT/PBA-FDH nano-bioelectrode with relevant reported studies. 
Sensor type Construction material Sensing method Sensing element  Matrix Linear dynamic 
range/ Sensitivity/ 
Detection limit 
Ref. 
Planar 
electrochemical 
transducers 
Potentiometric sensor – 
Si3N4-ISFET 
Conductometric and 
amperometric sensor – gold 
interdigitated electrodes 
vacuum deposited with 
sintered aluminum oxide 
 
Potentiometry, 
conductometry, 
and  amperomety 
Alcohol oxidase from 
Hansenula polymorpha 
10 mM Phosphate 
buffer (pH 7.7) 
150 – 9000 ppm 
 
 
47 
Enzyme biosensor Si/SiO2/Si3N4 structure  as 
physical transducers 
Capacitance NAD+ and glutathione-
dependent recombinant 
formaldehyde 
dehydrogenase 
2.5 mM Borate 
buffer (pH 8.40) 
0.3 – 600 ppm 
Sensitivity  
31 mV/ decade 
 
Detection limit  
0.3 ppm 
 
11 
Amperometric 
enzyme sensor 
Disks of woven graphite 
gauze 
Amperometry NAD+ and glutathione-
independent 
formaldehyde 
dehydrogenase from 
0.1 M KCl, 
80mM KH2PO4 
(pH 8.0) 
0.5 – 15 ppm  
Sensitivity  
0.39 µA/ppm 
19 
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Hyphomicrobium 
zavarzinii strain ZV 58 
 
Amperometric 
biosensor  
Platinized graphite electrode   
modified with low-molecular 
free-diffusing redox 
mediators or positively 
charged cathodic 
electrodeposition paints 
modified with Os-bis-N,N-
(2,2’-bipyridil)-chloride 
([Os(bpy)2Cl]) 
 
Amperometry NAD+ and glutathione- 
dependent 
formaldehyde 
dehydrogenase isolated 
from a gene-engineered 
strain of the 
methylotrophic 
yeast Hansenula 
polymorpha 
 
20 mM Phosphate 
buffer (pH 8.2) 
0.3 – 3 ppm 
Sensitivity    
358 Am−2 M−1 
 
Detection limit   
90 ppb  
 
20 
Electrochemical 
biosensor 
Glassy carbon electrode 
containing a membrane 
constructed with  
mesoporous silica materials 
 
Amperometry Formaldehyde 
dehydrogenase  
from Pseudomonas sp. 
Phosphate buffer 
(pH 7.4)  
30 ppb – 30 ppm  
Detection limit   
36 ppb 
21 
Electrochemical 
biosensor  
Screen-printed carbon 
electrode modified with 
MWCNT 
Amperometry Formaldehyde 
dehydrogenase  
from Pseudomonas 
putida 
PBS  (based on in 
situ released 
HCHO from a 
prodrug treated 
cancer cells in 
PBS) 
3 ppb – 3 ppm  
Detection limit   
300 ppb  
 
22 
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Electrochemical 
biosensor 
Screen printed gold 
electrodes modified with 
MWNT/PBA-FDH via the –
COOH groups of both 
MWNT and PBA 
Amperometry Formaldehyde 
dehydrogenase from 
Pseudomonas sp. 
10-times diluted 
urine (in PBS, pH 
7.4) 
Stirred solution 
analysis: 
100 ppb  - 16 ppm 
 
Sensitivity (based on 
the initial linear range, 
Fig. 3) 
174 nA/ppm 
 
Detection limit  
73 ppb 
 
Flow injection 
analysis: 
10 ppb – 10 ppm 
 
Sensitivity (based on 
the initial linear range, 
Fig. 3) 
 
342 nA/ppm 
 
Detection limit  
6 ppb 
This 
work 
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2.4 Conclusions 
Ther results presented confirm the analytical detection features of pyrenyl carbon nanostructure-
modified FDH bioelectrode for sensitive and selective quantitation of urine HCHO related to 
abnormal conditions that are known to result in elevated urine HCHO. The presented approach 
provides a viable nano-bioelectrode design for non-invasive detection of small-molecule markers 
for cancer and other diseases at clinically relevant ultra-low levels in complex matrices. Combining 
the current method with measurements of other biomarkers and assays of significance is expected 
to allow successful diagnostic outcome of an abnormal condition. By appropriate immobilization 
of marker specific-receptor molecules or enzymes coupled with a detection probe or mechanism, 
the proposed methodology is expected to allow broader applicability for quantitative measurement 
of any other small-molecule markers with selectivity. 
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CHAPTER 3   
 
 
ELECTROCHEMICAL AND SURFACE PLASMON CORRELATION OF SERUM 
AUTOANTIBODY IMMUNOASSAY WITH BINDING INSIGHTS: GRAPHENYL VS. 
MERCAPTO-MONOLAYER SURFACE  
3.1 Introduction 
The design of a reliable and reproducible biosensing assay platform with molecular insights into 
binding and quantitative nano-bio surface designs is significant for successful diagnostic 
applications. Serum concentration of autoantibodies has been proposed to associate with the 
occurrence of type 1 diabetes (T1D).1,2 T1D is a chronic immune disorder that results from the 
destruction of β-cell function in the islets of Langerhans, causing deficient insulin production and 
hyperglycemia.3 The etiology of T1D is largely unknown, but a combination of genetic 
predisposition, environmental factors, and a dysregulated immune system is believed to be the 
cause of the disorder.4-6 Over recent years, the prevalence of diabetes, in particular T1D has 
significantly increased from 5% to 10%. This has in turn affected the incidence of associated health 
complications on a large population of children and adults worldwide.7,8  
Pociot and Lernmark recently reported that T1D could be characterized by the appearance of β-cell 
autoantibodies at an early stage, and glutamic acid decarboxylase autoantibody (GADA) is one of 
them.9 In the early 1990s, GADA was recognized to interact with a 65-kDa autoantigen known as 
the glutamic acid decarboxylase-65 (GAD-65).
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Later, Urban and coworkers reported the association of GAD-65 and GADA immune complexes 
in stiff syndrome and T1D.10  GADA has been recognized as a highly valuable biomarker for the 
prediction of T1D, thus representing significance for the development of simple and accurate 
methods for early diagnosis of T1D. 
Figure 1. Design of graphenyl  and mercapto monolayer based immunosensors for biosensing and 
binding kinetics analysis. *Three electrode system in the 8xSPE array: gold working electrode 
(WE) and counter electrode (CE), pseudo Ag-reference electrode (RE). 
Over the past two decades, many research groups have demonstrated methods including 
radioimmunoassay (RIA),11 enzyme-linked immunosorbent assay (ELISA),12  chemiluminescent 
immunoarray (CLIA)13, and electrochemiluminescence assay14 for clinical diagnosis of T1D. Here 
we use an inexpensive ferricyanide reagent to demonstrate the electrochemical detection of GADA, 
compare the binding constants and analytical assay parameters, and provide quantitative insights 
into carboxylated graphene and mercapto-monolayer surface modifications (Figure 1).  
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As a novel class of two-dimensional nanocarbon material, graphene has recently attracted 
researchers in biomedical sciences for the development of sensitive electrochemical and optical 
devices.15-17  The high surface area to volume ratio, electrical conductivity, aqueous dispersibility 
suitable for screen-printed electrode surfaces, thin structure and apparent biocompatibility of 
carboxylated graphene makes it a unique carbon nanomaterial for biorecognition events and 
biosensing applications.18-20 Although, glucose and insulin biosensors are useful for diabetes 
management, non-glucose biomarkers are critical for enabling early diabetes prediction in children 
and adults.21-23 
To increase detection sensitivity, sensor surface modifications with various nanomaterials and 
selective isolation of analytes from complex sample matrices (e.g., blood, saliva, urine) by 
nanomaterials for amplified detection have been demonstrated.24-29  In particular, magnetic (MAG) 
beads are unique for the ease of magnetic isolation, separation, and highly sensitive detection of 
proteins, nucleic acids, and cells due to their high surface area and intrinsic magnetic properties.30-
34 Appropriate designs of the surface of MAG beads with specific capture molecules can be used 
to separate biomolecules selectively from complex clinical matrices to facilitate ultra-low detection 
with reduced nonspecific signals.30,31,35-37 In the present study, we demonstrate that by combining 
electrochemical immunosensing with surface plasmon resonance (SPR) spectroscopy, we can 
validate the electrochemical platform, and use the binding constant as a quality control checkpoint 
for large-scale production of the relatively inexpensive electrochemical sensors. 
Furthermore, in this work, a carboxylated graphenyl surface is quantitatively compared with the 
conventional mercapto-monolayer surface to obtain insights into analytical assay performance. The 
knowledge gained from the combined sensing and binding assessment is useful for developing 
reliable and better throughput clinical immunosensors for biomarker based diagnostic assays. 
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3.2 Experimental  
3.2.1 Materials and chemicals 
Eight-channel screen-printed gold electrodes (8xSPE) were purchased from DropSens, Spain 
(Product No. 8x220BT). SPR imaging (SPRi) gold array chips (Spot Ready 16, 1 mm diameter 
gold spots) were purchased from GWC Technologies (Madison, WI).  Carboxylated graphene 
(graphene-COOH) was purchased from ACS materials (Medford, MA). Glutamic acid 
decarboxylase-65 antigen (GAD-65) was bought from Creative Diagnostics (Shirley, NY, USA). 
Monoclonal glutamic acid decarboxylase autoantibody (GADA), bovine serum albumin (BSA, ≥ 
98%), aminoferrocene, 3-mercaptopropionic acid (MPA, ≥99%), 1-ethyl-3-[3-(dimethylamino) 
propyl] carbodiimide (EDC), and N-hydroxysuccinimide (NHS) were purchased from Sigma (St. 
Louis, MO, USA). Normal human serum was purchased from Atlanta Biologicals (Flowery 
Branch, GA, USA).  
Human serum samples were diluted 10-times in phosphate buffered saline (PBS), pH 7.4. Protein 
A/G coated magnetic beads (MAG-protein A/G, 2 µm, 10 mg mL-1) were purchased from Biotool 
(Houston, TX, USA). The beads contain 9.3×1013 protein A/G molecules/cm2 (Biotool). All other 
chemicals used were analytical grade. A NanoOrange Protein Quantitation Kit was purchased from 
Thermo Fisher Scientific (Waltham, MA, USA).  The commercial GADA ELISA kit was 
purchased from MyBioSource, Inc. (San Diego, CA, USA). The reagents were prepared using ultra-
pure water (Invitrogen Corporation, Grand Island, NY, USA). All measurements were carried out 
at room temperature (23 ˚C).  
3.2.2 Instrumentation 
Electrochemical impedance spectroscopy (EIS) measurements were performed to characterize the 
sensor surface modification as well as measure the GADA concentration dependent increase in 
charge transfer resistance (Rct) for ferricyanide/ferrocyanide redox probe added in solution. For the 
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EIS, an Interface 1000 potentiostat/galvanostat/ZRA from Gamry Instruments was used 
(Warminster, PA, USA).  
Surface plasmon measurements of GADA-GAD-65 interaction were made using GWC SPR 
imager-II (Horizon SPR imager model, GWC Technologies, Madison, WI). A light source with an 
operating wavelength of 800 nm was used. Real-time reflectivity changes followed by imaging of 
these changes as pixel intensity was completed using a charge-coupled device. The SPR curves 
were fit for kinetic analysis using TraceDrawer Software (Ridgeview Instruments AB, Vänge, 
Sweden). 
ELISA measurements were performed using a Biotek Synergy H1 Plate Reader based on 
UV/VIS/Fluorescence quantitation (BioTek Instruments, Inc., Winooski, VT, USA).   
Characterization of each step of the surface modification was conducted by scanning electron 
microscopy (SEM, Model: FEI Quanta 600FE) at an accelerating voltage of 20 kV. The images 
were acquired using FEIxT Microscope Control Software. Additional characterization of the sensor 
designs was conducted by Fourier transform infrared spectroscopy (FTIR, Thermo Scientific 
Nicolet iS50) operated in the attenuated total reflection mode using a diamond crystal. 
NanoOrange protein quantitation kit that works based on fluorescence was employed for 
quantifying the surface immobilized GAD-65 by measuring the difference in GAD-65 
concentration in solution before and after the immobilization step (Varian Cary Eclipse 
Fluorescence Spectrophotometer). 
3.2.3 Fabrication of the electrochemical immunosensor  
Each gold disk working electrode (geometric area = 0.2 cm2) of 8xSPE arrays were drop-coated 
with a 3.5 µL aliquot of a well-dispersed aqueous solution of carboxylated graphene (2.0 mg          
mL-1). The electrodes were placed in an oven (50 oC) for 30 mins in order to dry-coat the graphene 
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on the gold surface. The electrodes were then washed well with deionized water. For comparison, 
a conventional monolayer of MPA on 8xSPE arrays was prepared by incubating the working 
electrodes with 3.5 µL of 2 mg mL-1 solution of MPA in ethanol for 4 h in a cold and moist 
environment. All further assay steps were carried out under ice cold conditions. Carbodiimide 
chemistry was followed to covalently link the surface lysine groups of GAD-65 (PDB: 2OKK, ~29 
surface lysine residues) to the electrode surface via surface carboxyl groups of graphene or a MPA 
monolayer.38-40 For this, the 8xSPEs were treated with 4 µL of a freshly prepared solution mixture 
of EDC (0.35 M) and NHS (0.1 M) in deionized water for 20 min to activate the carboxyl groups 
to converting them to amine reactive N-succinimidyl esters. Following removal of unreacted 
reagents with deionized water, 3.5 µL of GAD-65 solution (6.5 µg mL-1 in PBS) was placed on 
each electrode of the arrays to covalently link GAD-65 through formation of amide bonds with the 
activated surface carboxyl groups for a duration of 30 min. After washing the unbound antigens 
with PBS, the free graphene surface was blocked for 15 min using 3 µL of a 1% BSA solution 
prepared in PBS. Finally, 3.5 µL of MAG-protein A/G-captured 10% serum GADA samples of 
various concentrations were added on the electrodes and allowed to incubate for 1 h. The modified 
immunosensor was rinsed in PBS to remove any unbound molecules and used for electrochemical 
measurements.  
3.2.4 Magnetic bead-protein A/G capturing of autoantibody from 10% human serum (MAG-
protein A/G-GADA)  
MAG beads functionalized with surface protein A/G molecules offer binding sites with orientation 
for capturing antibodies from serum. The capturing procedure followed the instructions provided 
by the manufacturer with slight modifications. In brief, 25 µL of MAG-protein A/G beads were 
washed twice with 150 µL of phosphate buffered saline (PBS, pH 7.4, 10 mM phosphate, 0.14 M 
NaCl, 2.7 mM KCl), and separated out using a small piece of magnet after each wash. The beads 
were then washed twice in 150 µL of binding buffer (50 mM tris, 150 mM NaCl, 0.1% Tween 20, 
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pH 7.5). Different concentrations of GADA spiked in 10% normal human serum in the binding 
buffer (250 µL) were added to separate aliquots of MAG-protein A/G beads and rotated in a tube 
rotor (Fisher Scientific) for 1 h at room temperature.  Upon completion of the incubation, the 
contents were suspended by pipetting in and out for 10 times, and the supernatant was removed 
immediately from the magnetically separated beads. The beads were washed two times with 300 
µL of the binding buffer. Finally, the beads were suspended to a final volume of 200 µL in the 
binding buffer. The MAG-protein A/G captured serum GADA samples were stored at 4 oC and 
used for up to 5 days.  
3.2.5 SPRi microarray modification  
Prior to use, the SPRi gold array chip was cleaned in piranha solution (3:1 mixture of concentrated 
H2SO4 and 30% H2O2 for 10 seconds. Caution: Piranha solution is highly corrosive and a strong 
oxidizer). First, 0.30 µL of 0.1 mg mL-1 of carboxyl-functionalized graphene (graphene-COOH) 
was dry-coated on each gold spot of the SPRi chip (1 mm diameter) and dried at 50 °C for 30 
minutes. The chip was then washed thoroughly with deionized water to remove any unbound 
material. Following the dry-coating, the immobilization of GAD-65 and BSA blocking steps were 
similar to that described above for the electrochemical immunoassay. The chip was then mounted 
in the SPRi instrument to monitor real-time reflectivity changes upon the binding of various 
concentrations of serum GADA captured onto MAG-protein A/G beads. Once the steady state 
response was reached, the SPR chip surface was rinsed well with PBS (pH 7.4) to remove any 
unbound molecules present in the bulk solution and to attain a new baseline signal. Similar SPR 
measurements were taken for an immunosensor prepared with a self-assembled monolayer of MPA 
instead of the graphene-COOH modification.  
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3.2.6 Quantitation of GAD-65 on the immunoassay surface  
The amount of GAD-65 bound per electrode was quantified using a NanoOrange protein 
quantitation kit as follows: A calibration curve was obtained for various concentrations (2 – 10 ng 
mL-1) of GAD-65 prepared in the NanoOrange working solution provided in the assay kit. The 
solutions were heated at 95 oC for 10 min in the dark followed by cooling to room temperature for 
20 min before measuring fluorescence intensity. GAD-65 (3.5 µL of  6.5 µg mL-1) was then coated 
onto each carboxyl activated graphene working electrode for 30 min and washed twice with 5 µL 
aliquots of PBS. The wash solutions were collected and made up to 2 mL with the NanoOrange 
working solution. A similar heating and cooling protocol as described above was followed before 
measuring the fluorescence intensity (excitation at 465 nm and emission at 603 nm). From the 
difference in fluorescence of free GAD-65 before and after surface immobilization, the amounts of 
GAD-65 immobilized on the graphene-COOH and MPA surfaces were estimated. 
3.2.7 Quantitation of surface carboxyl groups based on electroactive aminoferrocene 
functionalization of graphene-COOH or MPA monolayer surface on 8xSPEs  
8xSPEs were dry-coated with graphene-COOH or with a self-assembled monolayer of MPA (one 
8xSPE was used for each modification) followed by carbodiimide activation of the surface carboxyl 
groups using the EDC (0.35 M)/NHS (0.1 M) solution mixture. A 4.5-µL solution of 1 mM 
aminoferrocene in PBS, pH 7.4 was then placed on the –COOH activated electrodes and incubated 
for 45 min in a cold and moist atmosphere. To ensure the covalent strategy of linking, we prepared 
graphene-COOH or MPA modified 8xSPEs with an electrostatically adsorbed layer of 
aminoferrocene. The electrodes were then rinsed with deionized water to remove any unbound 
molecules. Cyclic voltammograms (CVs) were recorded to calculate the electroactive 
aminoferrocene molecules, and in turn, the relative amounts of –COOH groups on graphene-COOH 
and MPA surfaces.  
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3.2.8   Electrochemical measurements of serum GADA by an immunoassay 
Faradaic impedance measurements for various concentrations of MAG-protein A/G captured serum 
GADA (10% normal human serum) bound onto GAD-65 were performed at room temperature (23 
oC) in an aqueous electrolyte solution containing 0.1 M KCl and 10 mM each of Fe(CN)63-
/Fe(CN)64- as the redox probe. A potential of 0.2 V vs a pseudo Ag reference electrode was applied 
at an AC amplitude of 10 mV, and the frequency was scanned from 0.1-100 kHz. The experimental 
impedance data were fit by the Randles equivalent circuit model to determine the charge transfer 
resistance (Rct) values. Differential pulse voltammetry (DPV) was employed as a complementary 
technique that measured current signals. The same redox solution as of the EIS assay was used to 
measure the currents upon scanning the potential from +0.6 to -0.1 V vs a pseudo-Ag reference 
electrode (50 mV for amplitude, 10 mV step potential, 20 ms sampling width, and 50 ms pulse 
width). Each experiment was replicated five times to obtain the average responses with good 
reproducibility.   
3.3 Results and Discussion  
3.3.1  Optimization of GAD-65 concentration on the immunosensor surface 
The immunosensor responses for various concentrations of GAD-65 used for surface 
immobilization (325 ng mL-1 – 13 µg mL-1 in PBS, pH 7.4) (Fig. 2) upon binding of a constant 
serum concentration of GADA (4 ng mL-1 in 10% human serum) captured onto the MAG-protein 
A/G beads were measured. This procedure allowed us to identify the optimum GAD-65 
concentration that provided the maximum Rct signals for GADA binding. The Rct values measured 
by Faradaic impedance spectroscopy for increasing concentration of surface immobilized GAD-65 
antigen, are shown in Figure 2. No appreciable change in the Rct was observed beyond 6.5 µg mL−1 
of GAD-65 concentration. Therefore, we chose this solution concentration of GAD-65 to 
immobilize on the designed graphene-COOH surface for the immunosensor. 
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The amount of surface immobilized GAD-65 on the graphene-COOH modified surface was 
estimated to be 17 ± 2 pmol cm-2 when using a solution concentration of 6.5 µg mL-1 of GAD-65. 
This estimation was based on the difference in free GAD-65 amount in solution before and after 
immobilization (NanoOrange protein quantitation kit). The immobilization efficiency of GAD-65 
was 76 ± 4% under the experimental conditions followed. 
 
 
 
 
 
 
 
 
Figure 2. Rct values for increasing solution concentration of GAD-65 (in PBS solution) used for 
immobilization onto the carbodiimide activated graphene-COOH/gold surface, and followed by the 
binding of a constant concentration of 10% serum GADA (4 ng mL-1) captured onto MAG-protein 
A/G beads. 
3.3.2 Hydrodynamic size and zeta potential measurements 
We noted that the capturing of GADA from 10% human serum onto the MAG-protein A/G beads 
caused an increase in the average hydrodynamic size, and a negative shift in the Zeta potential of 
the beads (Table 1). This shift is reasonable because the IgG antibody has a net negative charge at 
pH 7.4 (isoelectric point is 6.1-6.5).41  
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Table 1. Hydrodynamic size and Zeta potential values of MAG-protein A/G and MAG-protein 
A/G-GADA beads (five times diluted in PBS, pH 7.4), temperature 25 oC. 
Particle type Hydrodynamic size 
(nm) 
Zeta potential 
(mV) 
MAG-protein A/G 1980 ± 49 -16 ± 1 
MAG-protein A/G-serum GADA 2061 ± 37 -22 ± 2 
 
The samples used for the hydrodynamic and Zeta potential analysis were five times diluted in 
PBS. This dilution was required to facilitate measurements within the saturating limit of the 
detector in the instrument. 
 
3.3.3 Microscopic characterization of the graphene immunosensor  
The SEM images acquired at each step of the immunoassembly on an 8xSPE array are presented 
in Figure 3 – A to D. We identified that a rough Au surface (gold-ink cured on a ceramic substrate 
at low temperatures, DropSens Inc.) provided better reproducibility of the immunoassay than a 
smooth gold surface (DRP-8x220BT- U20, DropSens Inc.). This is likely due to the stronger 
adhesion of the graphene-COOH onto the rough Au over a smooth Au surface. Also, we determined 
that the aqueous suspension of graphene-COOH is more suitable for dry coating on screen printed 
electrodes than an organic solvent dispersion based carbon nanomaterials. This is because the 
screen-printed electrode surface tends to wear away when exposed for longer duration in organic 
solvents during the dry-coating process of nanomaterials.  
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Figure 3. SEM images of A. rough 
AuSPE surface, B. after dry coating 
of an aqueous suspension of 
graphene-COOH, C. after covalent 
attachment of GAD-65 antigen and 
surface blocking with 1% BSA, and 
D. after the binding of GADA spiked 
in 10% human serum (0.05 ng mL-1) 
and captured onto MAG-protein A/G 
beads. 
 
 
Fig. 3-A shows the image for the rough Au surface of an 8xSPE array. Dry coating of graphene-
COOH on the AuSPE surface resulted in spherical mesh-like and thread-like features (Fig. 3-B).42 
The graphene surface features became denser upon the covalent immobilization of GAD-65 antigen 
followed by blocking with a solution of 1% BSA in PBS (Fig. 3-C). After the binding of the MAG-
protein A/G-GADA conjugate onto the surface GAD-65 sites, the appearance of spherical MAG 
bead features on the electrode surface can be seen (Fig. 3-D). 
3.3.4 Spectroscopic characterization of the graphene immunosensor  
FTIR spectra further confirmed the results obtained from the SEM image analysis. The bare AuSPE 
surface did not show any peak in the measured region of the IR spectrum (Fig. 4-a). Upon coating 
with graphene-COOH (Fig 4-b), the appearance of a strong and broad peak at about 3219 cm-1 was 
attributed to the hydroxyl vibration of surface carboxyl groups.43 Additionally, the peaks at 1719 
cm-1 and 1078 cm-1 are characteristics of the stretching vibrations of carboxylic acid and other 
surface carbonyl groups.44 Upon activation of the surface carboxyl groups using EDC/NHS 
chemistry, the characteristic decrease in the O-H stretching vibration was observed (Fig 4-c). 
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Additionally, new peaks centered at 1764 and 1043 cm-1 corresponding to the C=O and C-O 
stretching vibrations of the succinimidyl esters from the EDC/NHS modification were present.45,46   
Figure 4. FTIR spectra of a. 
rough gold 8xSPE, b. after 
dry-coating with graphene-
COOH, c. after EDC/NHS 
activation, d. after GAD-65 
immobilization, and e. after 
the binding of 5 ng mL-1 
concentration of 10% serum 
GADA captured by the 
MAG-protein A/G beads. 
 
The protein amide-I band at 1639 cm-1 and amide-II band at 1547 cm-1 were observed due to the 
formation of amide bonds after the covalent attachment of the GAD-65 antigen with the graphene-
COOH surface (Fig 4-d).46,47  In addition, a new peak at 3324 cm-1 indicated the N-H stretching 
vibration of the protein. Once the serum GADA carried by the MAG-protein A/G beads was bound 
to the surface GAD-65 antigen, a new peak appearing at 602 cm-1 was assigned to the Fe-O 
stretching of Fe3O4 magnetic beads (Fig. 4-e).48  Furthermore, a slight shift in the amide-I and 
amide-II bands was possibly the result of complexation of GAD-65 with GADA. In addition, the 
N-H bending vibration peak at 794 cm-1 became more prominent due to the overall increase in the 
total protein molecules on the surface as the result of GADA-GAD 65 immunoassembly formation.  
3.3.5 Electrochemical impedance spectroscopy characterization of the immunosensor 
fabrication  
The stepwise construction of the immunosensor assembly starting from the bare gold 8xSPE to the 
GADA binding measurement step was characterized by Faradaic EIS as shown in Figure 5 with 
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Nyquist plots. An aqueous solution containing 0.1 M KCl and a mixture of 10 mM of each 
potassium ferricyanide and potassium ferrocyanide [Fe(CN)63-/4-] was employed as the redox probe 
in solution. The Randles equivalent circuit model was used to fit the experimental impedance 
spectra and obtain the Rct values. The Rct corresponds to the diameter of the semicircular region in 
the Nyquist plot.49 
         
 
 
 
 
 
 
Figure 5. Faradaic impedance spectroscopic measurements in an aqueous solution containing 0.1 
M KCl and 10 mM each of Fe(CN)63-/4- mixture: (a) AuSPE (3310 ± 101 Ω), (b) after dry-coating 
of graphene-COOH (1054 ± 154 Ω), (c) after covalently attaching GAD-65 by the carbodiimide 
coupling chemistry (2108 ± 67 Ω), (d) after blocking the free surface with 1% BSA (4190 ± 410 
Ω), and (e) after the binding of serum GADA (0.04 ng mL-1) captured onto the MAG-protein A/G 
beads (9290 ± 580 Ω). Experimental conditions: 0.2 V vs Ag/AgCl, amplitude 10 mV, and 
frequency range 0.1 - 100 kHz. 
Figure 5 (curve a) corresponds to the Nyquist plot of a rough Au surface of 8xSPE. Carboxylated 
graphene modification of the Au surface decreased the Rct, implying an increased surface 
conductivity favorable for the redox probe to communicate with the electrode (Fig. 5-curve b). This 
higher conductivity is advantageous to increase interfacial charge transport from the redox probe 
to the electrode, and subsequently facilitate sensitive monitoring of Rct changes. Immobilization of 
the GAD-65 antigen (Fig. 5-curve c), subsequent BSA blocking of the free electrode surface (Fig. 
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5-curve d), and the binding of serum GADA (0.04 ng mL-1) carrying MAG-protein A/G beads onto 
the surface GAD-65 increased the Rct values (Fig. 5-curve e). 
3.3.6 Estimation of signal enhancement and reduction of non-specific signals by the MAG-
protein A/G beads over the direct use of serum GADA solution  
Results indicate that the MAG-protein A/G bead strategy to isolate GADA from serum reduced the 
non-specific background signals from proteins and other components present in the free serum 
matrix, and thus offered an enhanced sensitivity (Fig. 6-A).50-52 Although protein A/G is not 
selective for capturing GADA alone, but to all serum antibodies, the designed immunosensor is 
successful in measuring the low GADA concentration above the nonspecific control serum-treated 
MAG-bead signals (no spiked GADA). 
Figure 6. A. Rct values for the BSA blocked, graphene-COOH coated gold surface immobilized 
with GAD-65 upon the binding of MAG-protein A/G beads alone (1.25 mg mL-1), GADA (2 ng 
mL-1) spiked in 10% serum in PBS (pH 7.4), and serum GADA (2 ng mL-1) captured onto the MAG-
protein A/G beads. B. Reduced non-specific background signals for MAG-protein A/G added to 
GADA unspiked serum compared to the GADA unspiked free serum solution. 
Furthermore, Fig. 6-A shows that the Rct signal enhancement for the binding of 2 ng mL−1 serum 
GADA captured with MAG-protein A/G beads was ~3-times greater than the direct use of GADA 
spiked 10% serum samples not captured onto the beads. This is the result of reduced nonspecific 
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signals from the MAG-protein A/G strategy over the free serum background signals (Fig. 6-B). The 
simplicity of magnetic capturing and isolation of the bound GADA from free serum by the MAG-
protein A/G beads is not feasible with other non-magnetic nanomaterials,53, which would require 
centrifugation and other tedious separation procedures. 
3.3.7 Serum GADA concentration dependent increase in charge-transfer resistance  
The Faradaic impedance responses and the respective calibration plots are presented in Fig. 7-A to 
D. The Rct of GAD-65 sensor surface increased with the binding of increasing serum GADA 
concentration (10% serum in PBS) captured with the MAG-protein A/G beads. This trend suggests 
that the increase in surface bound GADA carried by the MAG-protein A/G beads from the specific 
complexation with GAD-65 antigen sites increased the resistance to the ferri/ferrocyanide redox 
probe added in solution over the control serum treated with magnetic-protein A/G beads (no spiked 
GADA). 
The results infer that the graphenyl sensor compared to the MPA monolayer modified sensor (0.04–
0.75 ng mL−1) displayed a wider dynamic range of 0.02 - 2 ng mL−1 and several thousands enhanced 
Rct values for the same GADA concentration. The slope of the response curve in the linear range 
corresponds to the sensitivity of the sensor. A sensitivity enhancement of about 3-fold was observed 
for the graphenyl surface over the MPA modified surface (slopes in Figures-6C and 1D). The 
detection limits (three times the standard deviation of the control response/slope of the calibration 
graph) were 48 and 124 pg mL−1 for the graphenyl and MPA modified immunosensors, 
respectively. It is evident that the large surface area and -COOH functional groups on graphene-
COOH are favorable for high-density immobilization of surface biomolecules to detect lower 
concentrations of analytes than the MPA monolayer sensor. The clinically relevant serum GADA 
concentration range has been reported to be 0.03–19.9 nM, or 1.95 ng mL−1–1.29 µg mL−1.54 
Saturation behavior on the assay response was observed beyond 2 ng mL−1 serum GADA. 
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Although, higher concentrations of GADA will require a dilution to measure in the designed assay 
platform, several biomarkers with clinically relevant low nM concentrations can directly benefit 
from the assay. 
Figure 7. Nyquist plots obtained from the Faradaic impedance measurements in an aqueous 
solution containing 0.1 M KCl and 10 mM each of Fe(CN)63-/Fe(CN)64- for various concentrations 
of surface bound serum GADA immunoassembly : A. Graphene-COOH (0.02, 0.05, 0.1, 0.25, 0.5, 
0.75, 1, and 2 ng mL-1) and B. MPA (0.02, 0.05, 0.1, 0.25, 0.5, and 0.8 ng mL-1) modified 
immunosensors.C and D represent the dynamic range of respective response plots for Rct changes 
with concentration of GADA for N = 3 replicates. Ten percent serum not spiked with any GADA 
but treated with the MAG-protein A/G beads was used as the control sample, and its Rct value was 
subtracted from each of the GADA spiked serum sample responses. (Experimental conditions:      
0.2 V vs pseudo-Ag reference electrode, amplitude 10 mV, and frequency range 0.1–100 kHz.) 
3.3.8 Comparison of SPR responses for graphene-COOH and MPA modified immunosensor 
and bimolecular kinetic analysis 
The kinetic parameters from the real-time binding of surface immobilized GAD-65 with MAG-
protein A/G beads captured with serum GADA were determined by use of an SPRi assay. The 
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experimentally obtained SPR sensograms (Figure 8A and B) for different concentrations of GADA 
were fit into a 1:1 bimolecular kinetic model.33,55 The equations presented below were used to 
calculate the association rate (ka), the dissociation rate (kd), and the binding constant (KD) (Table 
2). The kinetic analysis was performed for the biomolecule interaction by assuming a 1:1 binding 
reaction as detailed below: 
A+B ⇌  AB       (1) 
Rate of association: 
d[AB]
dt
= ka[A][B]- kd[AB]  (2) 
Rate of dissociation: 
d[AB]
dt
= - kd[AB]    (3) 
where A is the GAD-65 antigen immobilized on the SPR chip, B is the GADA captured MAG-
protein A/G beads, and AB is the antigen-antibody complex formed. Since the concentration of A 
is constant, the antigen-antibody complex formation is considered to follow pseudo first order 
kinetics, where the SPR responses of the interaction with time is given as: 
dR
dt
= kaCRmax- (kaC+ kd)Rt     (4) 
The integrated form of (4) is given as: 
Rt= 
kaCRmax[1-e
-(kaC+ kd)t]
kaC+ kd
+ R0    (5) 
KD
app
= 
kd
ka
       (6) 
Where, Rt and Ro are the SPR responses at any time t and at t = 0 respectively, Rmax is the maximum 
reflectivity change, C is the concentration of serum GADA captured onto the MAG-protein A/G 
beads, ka is the apparent association rate, kd is the apparent dissociation rate, and KD
app
 is the 
apparent binding constant. The values of ka and kd were obtained by fitting the experimental SPR 
curves using the TraceDrawer kinetics software. 
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Figure 8. Simulated (red) and real-time SPR sensograms (black) for different concentrations (a to 
c) of 10% serum GADA, 0.05, 0.10, and 0.50 ng mL-1, captured with MAG-protein A/G beads and 
bound onto GAD-65 immobilized sensor surfaces modified with A. graphene-COOH and B. MPA. 
The lower KD value for the graphene-COOH modified SPRi chip suggests that graphene provides 
a stronger GADA-GAD-65 binding interaction [i.e., a more sensitive platform from an analytical 
perspective] through its increased number of surface carboxyl groups and plasmon enhancing 
feature when compared to the MPA modified chip. Moreover, the KD values of both MPA and 
graphene-COOH modified chips are smaller (better affinity) in comparison to the previously 
reported SPR assay value (KD = 1.37 nM) in PBS buffer medium on the surface of a mixed self-
assembled monolayer.56  This is more likely due to the signal enhancements from the MAG-protein 
A/G bead strategy offering a highly enhanced signal output than free GADA present in solution. 
Moreover, the MAG-bead based strategy was shown to allow a significantly greater amount of 
immobilization of surface antibodies due to the large number of particles with a net high surface 
area.57 This high-density antibody carrying beads are expected to facilitate a greater rate of 
association with surface GAD-65 molecules and a slower dissociation rate for graphene-COOH 
than the MPA surface (Table 2). A prior report estimated that over 100,000 molecules of antibody 
can be bound selectively to MAG-beads to obtain attomolar detection limits of prostate specific 
antigen.52,57  
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Table 2. Kinetic parameters for the MAG-protein A/G beads captured serum GADA binding onto 
a surface immobilized GAD-65 antigen. 
Kinetic parameters Graphene-COOH MPA 
Association rate constant, ka [M-1 s−1] 1.05 (± 0.13) × 109 0.90 (± 0.13) × 109 
Dissociation rate constant, kd [s−1] 3.2 (± 0.4) × 10−3 5.0 (± 0.6) × 10−3 
Binding constant, KD [pM] 3.0 ± 0.5 5.6 ± 1.0  
 
3.3.9 Validation of the graphene-COOH and MPA modified serum GADA 
DPV was employed as a complementary method to the impedimetric immunosensor. Decrease in 
DPV peak currents was observed with the increase in serum GADA MAG-beads binding to surface 
GAD-65. This is because the insulating character imparted on the electrode surface by the bound 
MAG-protein A/G-GADA beads onto GAD-65 is expected to decrease the redox currents of the 
added ferri/ferrocyanide probe in solution (Figure 9). The DPV results are in correlation with EIS. 
The limits of detection were 34 and 92 pg mL−1 for the graphene-COOH and MPA modified 
immunosensors, respectively, which are slightly lower than the EIS method. 
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Figure 9. DPV responses showing the decrease in currents for 10% serum containing GADA 
concentrations of a. 0.0, b. 0.02, c. 0.05, d. 0.1, e. 0.2, f. 0.5, and g. 0.75 ng mL-1 captured with 
MAG-protein A/G beads, and upon binding with the surface GAD-65 antigen on A. graphene-
COOH and B. MPA modified immunosensors. Experimental conditions: aqueous mixture 
containing 0.1 M KCl and 10 mM each of Fe(CN)63-/Fe(CN)64- with potential scanned from + 0.6 
to - 0.1 V vs a pseudo-Ag reference electrode. C and D represent the linear DPV responses of the 
immunosensors modified with graphene-COOH and MPA, respectively. 
 
3.3.10 Estimation of the relative surface carboxyl groups on graphene-COOH and MPA 
modified gold surfaces  
Figure 10-A and B show the cyclic voltammograms of the graphene-COOH and MPA coated 
electrodes covalently attached and electrostatically adsorbed with redox active aminoferrocene 
molecules (a and b, respectively, in each plot). Resulting peak currents and integrated peak areas 
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(charge in Coulombs) are directly proportional to the number of aminoferrocene molecules bound 
to either graphene-COOH or MPA surface. No redox peaks were shown by either the graphene-
COOH or MPA surfaces not immobilized with aminoferrocene, confirming no interferences from 
the surface modifications on the –COOH estimation (Insets of Figure 11-A and B). The linear 
dependence of the anodic current with scan rate suggested that the voltammetry of aminoferrocene 
molecules exhibited a surface confined redox process (Figure 11-C and D). 
Figure 10. Background subtracted CVs of A. graphene-COOH, B. MPA modified gold electrodes 
with a. covalently attached, and b. adsorbed films of aminoferrocene in argon purged PBS buffer, 
pH 7.4, 23 °C. The scan rate was 0.1 V s−1. 
The average formal potentials of the covalently attached aminoferrocene film on the graphene-
COOH and MPA surfaces were 112 ± 5 and 114 ± 8 mV, respectively. The electrostatically 
adsorbed films of aminoferrocene on each of the modified surfaces exhibited a similar formal 
potential as the covalent films. However, the covalent films enabled higher electroactive 
aminoferrocene immobilization than the electrostatic films as discussed below.  
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Figure 11. Background subtracted scan rate dependent CVs of the covalently attached 
aminoferrocene on A. graphene-COOH and C. MPA modified Au 8xSPEs and the respective plots 
of peak current vs scan rate (B and D). The scan rate inner to outer: 0.075 - 1.2 V s-1 at 23 oC, in 
PBS, pH 7.4. 
From the measured oxidation peak area, the electroactive surface coverage (Г, Eq. 1) of 
aminoferrocene and in turn the relative extent of carboxyl groups were determined.58 Q is the area 
of the oxidation peak of aminoferrocene, n is the number of electrons involved in the 
aminoferrocene oxidation (n = 1), F is the Faraday constant, and A is the area of the working 
electrode (A = 0.2 cm2). 
Г = Q / nFA       (Eq. 1) 
The Г values were also calculated from the anodic peak current by using Eq. 2,59 where Ip is the 
anodic peak current, ʋ is the scan rate, R is the universal gas constant (8.314 J mol−1 K−1), and T 
(296 K) is the temperature in Kelvin. 
Ip = n
2F2ʋAГ/4RT     (Eq. 2) 
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The peak area and peak current based estimations of Г agreed well with each other. The graphene-
COOH surface provided 9-fold greater surface carboxyl groups than the MPA monolayer surface 
(Table 3). 
Table 3. Estimated electroactive amounts of aminoferrocene on graphene-COOH and MPA 
modified electrodes. The estimations were based on anodic peak area (Q in nC) or peak currents 
(Ip in nA) from cyclic voltammograms shown in Fig. 9. 
Parameter Graphene-COOH MPA 
Covalently attached 
aminoferrocene 
Q (nC) 920.3 ± 86.6 98.1 ± 5.9 
Calculated Г 
(pmoles/cm2) 
47.6 ± 5.1 5.1 ± 0.3 
Ip (nA) 918.2 ± 76.2 108.3 ± 5.9 
Calculated Г 
(pmoles/cm2) 
48.6 ± 4.2 5.7 ± 0.6 
Adsorbed 
aminoferrocene 
Q (nC) 189.4 ± 15.4 31.0 ± 1.9 
Calculated Г 
(pmoles/cm2) 
9.8 ± 1.3 1.6 ± 0.11 
Ip (nA) 208.2 ± 28.3 34.2 ± 1.3 
Calculated Г 
(pmoles/cm2) 
11.2 ± 2.5 1.8 ± 0.2 
 
 
76 
     
 
3.3.11 Application to T1D patient samples and validation by a commercial ELISA kit  
We determined that the designed immunosensor platform is applicable to measure serum GADA 
concentrations in T1D patient serum samples. The samples were prepared in a similar manner as 
the spiked GADA serum standards, and captured onto MAG-protein A/G beads for detection upon 
binding onto surface immobilized GAD-65. A good correlation was obtained between our 
electrochemical immunoassay and the commercial ELISA kit (paired t-test performed at 95% 
confidence level). The dynamic range was sufficient to determine the sample GADA concentrations 
with a good precision (Table 4-A). 
Table 4. A. Results from the analysis of patient samples (10% serum) on the designed graphene-
COOH electrochemical immunosensor and ELISA (N = 3). B. Recovery data of the designed EIS 
immunoassay with the ELISA method for a patient serum sample spiked with GADA. 
A. T1D 
patient samples 
EIS immunosensor 
(ng mL-1) 
ELISA 
(ng mL-1) 
1 3.4 ± 0.2 3.0 ± 0.1 
2 2.2 ± 0.3 1.9 ± 0.2 
 
 
 
 
 
B. Method Spiked [GADA]   
(ng mL-1) 
Measured [GADA] 
(ng mL-1) 
Recovery % 
EIS 0.50 
2.50 
0.45 
2.34 
90% 
94% 
ELISA 0.50 
2.50 
0.46 
2.43 
92% 
97% 
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To assess the accuracy of our electrochemical assay, a known concentration of GADA was spiked 
to one of the patient serum samples. A recovery percentage of ≥90% was obtained from the 
electrochemical assay, which is comparable to the recovery in ELISA (Table 4-B). The 
electrochemical immunoassay presented takes less time than the ELISA method (EIS immunoassay 
~2 h 30 min, ELISA ~4h), requires smaller sample volumes (EIS immunoassay 3.5 μL per 
electrode, ELISA 100 μL sample per well), and with a reasonably good linear range (EIS 
immunoassay 0.02–2.0 ng mL−1, ELISA 0.16–5.0 ng mL−1). However, the EIS approach is 
throughput limited, because each impedance channel needs a separate potentiostat unit, hence an 
array-based impedance detection is an expensive approach. Therefore, our ongoing research 
direction is to translate the fundamental knowledge and assay designs derived from this work to 
develop a high-throughput cost-effective assay format. 
3.4 Conclusions 
The presented graphene modified immunosensor array successfully measured serum GADA levels 
at clinically relevant concentrations. The selectivity of GAD-65 on the sensor surface was useful 
to capture GADA carried by MAG-protein A/G beads. The combination of protein A/G coated 
MAG beads to separate GADA from serum samples minimized the effect of interferences from the 
serum matrix, and thus enhanced the detection sensitivity. Electrochemical and surface plasmon 
methods correlated with each other. Plasmon enhancing graphene-COOH offered better analytical 
detection features compared to a self-assembled monolayer of MPA. A good, statistically valid 
correlation was obtained for the electrochemical immunosensor with the commercial ELISA. 
Overall, the binding kinetics parameters can be used as an excellent quality control checkpoint for 
large-scale production of graphenyl biosensors for reliable applications in clinical diagnostic 
assays.  
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CHAPTER 4   
 
MEASURING ULTRA-LOW LEVELS OF NUCLEOTIDE BIOMARKERS USING QUARTZ 
CRYSTAL MICROBALANCE AND SPR MICROARRAY IMAGING METHODS: A 
COMPARATIVE ANALYSIS  
4.1 Introduction 
In recent years, DNA-based biosensors have received immense attention due to their applicability 
in the fields of gene sequencing,1 therapeutic and delivery systems,2 pathogen detection,3-5  and 
forensic studies.6 Single stranded DNA molecules can be used as inexpensive molecular analogs of 
RNA for assay methodology development for complex sample matrices. Recently, microRNAs 
(miRNAs) have become important genetic biomarkers for early diagnosis of various diseases, 
including cancer,7,8  and lung diseases.9,10 miRNAs are a group of small RNAs approximately 21–
25 nucleotides in length that function mainly by binding the 3ʹ-untranslated regions of specific 
target messenger RNAs (mRNAs) to repress protein translation or cleave mRNAs.11 In particular, 
miRNA-21 has been found to be relevant to infectious diseases, such as viral12  and bacterial13 
infections, as well as non-infectious diseases such as cardiovascular disorder14 and cancer.15 Hence, 
ultra-sensitive and selective detection of miRNA biomarkers present in a complex clinical matrix 
such as blood, plasma, or serum is significant for diagnostic applications.  
Adapted from G. Premaratne, Z. H. Al Mubarak, L. Senavirathna, L. Liu, and S. Krishnan, Measuring Ultra-
low Levels of Nucleotide Biomarkers Using Quartz Crystal Microbalance and SPR Microarray Imaging 
Methods: A Comparative Analysis, Sensors & Actuators: B. Chemical, 2017, 253,368–375 with permission 
from Elsevier. 
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Suitable structural features of a capture oligonucleotide probe are essential for selective 
hybridization with a target miRNA in the presence of other nucleotides. A quartz crystal 
microbalance (QCM) is a mass sensor that provides both qualitative and quantitative measurements 
by translating changes in the oscillation frequency of the quartz crystal to the corresponding mass 
changes.16  Surface plasmon resonance imaging (SPRi)17-19 is an emerging technique that is superior 
to conventional SPR for in situ detection of biomolecular interactions in real-time in a single 
microarray platform.20,21 SPRi offers simplicity and higher throughput compared to the 
conventional single sample analysis by allowing measurements at a fixed angle of incidence to 
directly collect reflectivity changes (ΔR%) across an array of gold spots.22 Furthermore, the SPRi 
microarray requires less assay time than conventional SPR to analyze several replicates at once 
leading to high precision.23,24 The hybridization of oligonucleotides with the SPR surface-
immobilized capture probe results in an increase in the refractive index. The use of gold 
nanoparticles (AuNPs) has been shown to increase the reflectivity changes of a hybridization 
reaction due to their effect on enhancing the surface plasmon signals.25-27 
In this study, an inexpensive target oligonucleotide containing a similar number of nucleotides to 
that of the miRNA-21 marker with thymine in place of uracil and with a poly-T tail and a free thiol 
group was designed to covalently attach to AuNPs via the well-known Au-thiol chemisorption.28 
The AuNP-linked mimic oligonucleotide was hybridized with a complementary surface 
immobilized capture probe. The effect of serum matrix percentage on the resulting detection signals 
for the miRNA-21 mimic was evaluated. Selectivity of the assay also was assessed using a five 
base pair mismatch-containing sequence as the control. Furthermore, we measured the changes in 
SPR reflectivity with an image output in the designed hybridization assay along with quantitative 
QCM mass analysis. Such oligonucleotide models are a cost-effective way to develop sensitive 
assay strategies for complex sample matrices, compare two analytical methods, and evaluate the 
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efficiency of a hybridization strategy that may be useful for measuring ultra-low levels of miRNA 
markers in circulating body fluids. 
4.2 Experimental 
4.2.1 Materials and chemicals 
Thiol-modified custom-designed oligonucleotides (sequences are presented in Table 1), 
dithiothreitol (DTT), 6-mercaptohexanol (MHOH), and NAP-10 columns were obtained from 
Sigma-Aldrich (Woodlands, TX, USA). AuNPs (50 nm diameter) were purchased from BBI 
Solutions (Cardiff, UK). Human serum samples were purchased from Fitzgerald Industries 
International Inc. (North Acton, MA, USA). SpotReady-16 gold spotted glass microarray chips 
(spot size 1 mm diameter, SPR-1000-016) were obtained from GWC Technologies (Madison, WI, 
USA).Gold disc infused quartz crystals (gold diameter 0.2 inch) used for the QCM were purchased 
from International Crystal Manufacturing Co, Inc.(Oklahoma City, OK, USA). All other chemicals 
were of high-purity analytical grade. To prepare all solutions, ultrapure distilled water (DNAse and 
RNAse free) purchased from Life Technologies (Carlsbad, CA, USA) was used.  
Table 1. Sequences of designed oligonucleotides.  
Surface capture 
Probe 
5′-HS-
TGTCAGACAGCCCATCGACTGGTGTTGCCATGAGATTCAACAG
TCAACATCAGTCTGATAAGCTACCCGACA-3ʹ 
Target 5′-HS-
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTAGCTTATCAGACTGATGTTGA-NH2-3ʹ 
Control 5′-HS-
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTAGGATATCACACTGATGAAGA-NH2-3ʹ 
The hybridization sequences for probe, target, and control are highlighted. Base pair mismatches 
of the control with respect to the target are highlighted in red. The addition of Poly-T50 segments to 
the target and control sequences provides stability and flexibility to the strands.29  
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4.2.2 Instrumentation  
The optical imaging experiments were performed using a SPRimagerII array instrument at room 
temperature (GWC Technologies). The experiments were conducted using a dual-channel set-up 
equipped with two syringe pumps (100 µL sample loop, New Era Pump System, Inc., Farmingdale, 
NY, USA) in order to assess hybridization of the target and control oligonucleotides with the 
surface capture probe. The Digital Optics V++ software package provided with the instrument was 
used to collect SPRi difference images (i.e., differences of the pixel intensities before and after 
hybridization events), and the images were visualized using ImageJ 1.49v software (National 
Institutes of Health, USA). 
The mass changes resulting from hybridization were measured using a QCM instrument (Gamry 
Instruments Inc., Warminster, PA, USA). Each modification step on the gold quartz crystal was 
performed offline, and the frequency changes were measured in the QCM system at a sample 
measurement interval of 0.1 s until a constant frequency response with time was reached. The 
fundamental oscillation frequency of the crystals was 10 MHz, and the QCM sensor surface was 
immersed in 0.1 M NaCl/0.1 M sodium phosphate buffer (pH 7.4) during measurements.  
A Nanodrop ND1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA) was used to 
quantify the surface capture probes immobilized on the SPR array or quartz crystal surface and 
additionally to quantify the target and control oligonucleotides linked to AuNPs. Surface 
characterization of the gold surface of the SPR microarray before and after coating with the surface 
capture probe was conducted by scanning electron microscopy (SEM, Model: FEI Quanta 600FE). 
An accelerating voltage of 20 kV was applied. The images were acquired using the FEIxT 
Microscope Control Software. 
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4.2.3 AuNP-linked oligonucleotide preparation  
The disulfide-modified oligonucleotide reduction protocol provided by the manufacturer (Sigma-
Aldrich) was followed to activate the oligonucleotides to link with the AuNPs. For thiol activation, 
the dry oligonucleotide samples were treated with an aqueous solution of DTT (100 mM) at a 10:1 
ratio (µL DTT to A260 units of oligonucleotides), which is sufficient to activate the thiol groups of 
the oligonucleotides.30 The reaction mixture was incubated for 1 h at room temperature. DTT and 
other reaction byproducts were removed using a NAP-10 column that was pre-equilibrated with 
approximately 15 mL of 50 mM sodium phosphate buffer (pH 6.0). The purified oligonucleotides 
were quantified by measuring absorbance at 260 nm using a Nanodrop spectrophotometer (1 mm 
path length light source; CCD array detector).31,32 The molar extinction coefficient of each 
oligonucleotide sequence was used to calculate concentrations (εprobe: 698.2, εtarget: 637.9, εcontrol: 
622.7 mM–1 cm–1, Sigma-Aldrich). 
AuNP-linked oligonucleotides were prepared with slight modifications to previously described 
methods.33-35 Briefly, 250 µL of test concentrations (50 fM – 50 pM) of the target and control 
oligonucleotides were prepared in sodium phosphate buffer (pH 6.0), mixed with 100 µL of 50 nm 
AuNP solution, and incubated for 4 h at 37 oC. At the completion of incubation, 150 µL of 1 M 
NaCl/0.1 M sodium phosphate buffer (pH 7.4) and 350 µL of distilled water were added, and the 
samples were left to age in an incubator for 24 h at 37 oC. The samples then were centrifuged at 
12,500 rpm for 45 min to remove the supernatant, and the precipitate obtained was rinsed twice 
with 0.1 M NaCl/0.1 M sodium phosphate buffer (pH 7.4). Samples were resuspended to the 
original volume of 250 µL using the same buffer solution for both SPRi and QCM analysis. The 
calibration plot generated for the AuNP-target oligonucleotide conjugates was used to assess the 
recovery when the target oligonucleotide was dissolved in various percentages of human serum. 
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4.2.4 Quartz crystal surface modification and detection 
New gold-coated quartz crystals were washed with ethanol followed by distilled water and dried 
under N2 gas prior to surface modification steps. Each crystal was incubated with 20 µL of thiol-
activated probes for 4 h in a moist and cold environment (4 oC) following a wash with phosphate 
buffer (pH 7.4). The free surface was blocked using 25 µL of 5 mM MHOH, followed by a wash 
with distilled water after a 30 min incubation. The initial oscillation frequency was measured by 
QCM in solution mode. The surface capture probe-modified quartz crystals were exposed to 20 µL 
of AuNP-linked control oligonucleotide for 45 min and then washed with 0.1 M NaCl/0.1 mM 
sodium phosphate buffer (pH 7.4) to remove any unbound material from the crystal surface. 
Decrease in the oscillation frequency was measured on the modified quartz crystal surface. The 
same crystals were exposed to 20 µL of AuNP-linked target oligonucleotide (miRNA-21 mimic) 
and incubated for 45 min. Decrease in the frequency of the quartz crystal was measured after 
washing with 0.1 M NaCl/0.1 M sodium phosphate buffer (pH 7.4) to remove any unbound target 
oligonucleotide. Separate experiments were conducted using the target and control 
oligonucleotides that were devoid of AuNP conjugation to assess the signal amplification resulting 
from the AuNP linkage strategy.   
4.2.5 Modification of the SPR microarray surface and detection 
After an initial wash step of the SPR gold array chip with ethanol, 20 µL of thiol-activated capture 
probes (Figure 1) were added to 12 spots and incubated for 4 h in a moist and cold environment (4 
oC), followed by washing with phosphate buffer (pH 7.4). The free surface of the whole array was 
blocked by incubation with 25 µL of 5 mM MHOH for 30 min to minimize nonspecific binding 
interactions. The modified chip was immediately placed on the SPRi dual flow channel system. 
The chip-prism contact surface was filled with a layer of index matching fluid (Cargille Labs, Cedar 
Grove, NJ, USA). Two sample injector units and two syringe pump systems were connected to the 
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flow channels. Real-time measurements were taken using the running buffer, 0.1 M NaCl/0.1 M 
sodium phosphate buffer (pH 7.4). 
 
 
 
 
 
 
 
 
Figure 1. Fabrication procedure of the SPR microarray chip for selective detection of the target 
miRNA-21 mimic (T) from the control (C) oligonucleotide sequence by hybridization in a dual 
channel SPRi system. 
The running buffer was pumped at a flow rate of 50 µL/min, and a reference image of the array 
was taken. The dual sample injector loops (100 μL volume) were then separately filled with 
suspensions of target or control oligonucleotide-conjugated AuNPs in 0.1 M NaCl/0.1 M sodium 
phosphate buffer (pH 7.4) and allowed to pass onto the capture probe-modified array surface for 
45 min. Upon completion of the incubation, the chip surface was washed for 10 min with the 
running buffer to remove all unhybridized oligonucleotides present in solution. The final images 
of the microarray, after introducing target and control oligonucleotides, were acquired using a CCD 
camera. The difference between the images taken before and after the hybridization events were 
obtained as SPR pixel intensity changes, which can be represented in a 3D format using ImageJ 
software. Gold spots treated with only the blocking reagent were used to assess nonspecific signals. 
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Two control spots and six test spots each for detecting the target and control nucleotides were 
designed within the same microarray chip, which minimized spot-to-spot variations among 
different chips. The average SPR pixel intensities and standard deviations were calculated from the 
results obtained for six test spots with three replicate measurements. 
4.3 Results and Discussion 
4.3.1 Spectroscopic analysis of AuNP-linked oligonucleotides 
Figure 2 shows the UV-vis spectra of unmodified AuNPs in aqueous solution and AuNPs linked 
with 5′- thiol modified control and target oligonucleotides in 0.1 M NaCl/0.1 M sodium phosphate 
buffer (pH 7.4). After linking AuNPs to the target and control oligonucleotides, the Soret band 
absorbance shifted from 517 nm to 526 and 524 nm, respectively.  
Figure 2. UV-visible spectra of (a) AuNPs 
before conjugation to oligonucleotides and 
AuNPs linked to (b) target or (c) control 
oligonucleotide present in 0.1 M NaCl/ 0.1 
M sodium phosphate buffer (pH 7.4).  
 
 
 
 
The shift could be a result of surface modifications that occurred on the AuNPs and/or the 
centrifugation step used to separate the AuNP-linked oligonucleotides affecting the particle size 
distribution.36 The oligonucleotide linking to AuNPs was free of aggregate formation, as no drastic 
changes in the absorption band or decrease in peak intensity were detected. Aggregation of 13 nm 
AuNPs upon conjugation with thiolated oligonucleotides has been shown to red shift the Soret 
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band.37 Thus, the absence of notable aggregation in our system was possibly facilitated by the 
relatively larger AuNPs (50 nm) and/or negatively charged citrate stabilization of the AuNPs that 
repel particle aggregation.38  
Table 2 presents the results of quantitation of thiol-activated oligonucleotides before and after 
attachment to gold surfaces, which was performed to estimate binding efficiency. The 
immobilization efficiency of the surface capture probe was slightly greater for the QCM than for 
the SPR microarray. This can be attributed to the larger surface area provided by the gold disc of 
the QCM crystal (0.2 cm2) compared to the gold spots of the SPR microarray (0.008 cm2). Binding 
of the surface capture probe to the gold surface of the quartz crystal resulted in a frequency change 
of 979 ± 18 Hz, which corresponded to a mass change of 662 ± 12 ng. This correlates with the 
results obtained from Nanodrop analysis of the surface capture probes that were bound to the quartz 
crystal.  
Table 2. Quantitation of oligonucleotides immobilized on the QCM or SPR gold surface and 
conjugated to AuNPs (N = 3 replicates). 
Molecule 
type 
Surface used to 
bind 
Amount 
introduced 
(pmoles) 
Amount 
bound 
(pmoles) 
Average 
percentage 
binding 
Surface 
capture probe 
(9.3 nM) 
SPR microarray 461.4 ± 26.8 375.3 ± 39.6 81% 
Quartz crystal 461.4 ± 26.8 406.5 ± 41.7 88% 
Target        
(10 nM) 
AuNPs 2.48 ± 0.35 2.17 ± 0.23 87% 
Control      
(10 nM) 
AuNPs 2.52 ± 0.41 2.27 ± 0.16 91% 
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Capture efficiencies of >80% suggest that the design of the surface capture probe on the gold 
surface of the quartz crystal and microarray was efficient and that the strategy for AuNP 
conjugation of target and control oligonucleotides was effective. The globular morphologies that 
appeared after modifying the SPR microarray surface with capture probes are presented as SEM 
images (Fig. 3A–C). 
Figure 3. SEM images of (A) a bare gold spot of the SPR microarray before modification and (B) 
the gold spot self-assembled with the thiol-activated surface capture probe. (C) Higher 
magnification image of (B). 
 
4.3.2 Assessment of target hybridization and signal amplification by the mass sensor 
We quantified the mass changes that occurred on the quartz crystal (Δm) based on the observed 
decrease in oscillation frequency for successive modification steps and by using the Sauerbrey 
equation: 
∆𝑓 =  
− 2 𝑓𝑜 
2 ∆𝑚
𝐴 √𝜇𝜌
 
where Δf is the frequency change from the mass adsorbed, fo is the fundamental frequency of 
oscillation (10 MHz), A is the geometric area of the gold disc bonded to the quartz crystal (0.2 
cm2), μ is the shear modulus of the quartz crystal (2.947 × 1011 dyn cm−2), and ρ is the density of 
the quartz crystal (2.648 g cm−3).39-41 The Sauerbrey equation, used to calculate the mass bound on 
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to the quartz crystal, has a thousand times greater sensitivity compared to an electronic balance 
with 0.1 µg sensitivity.42  
Figure 4. A. Mass changes for the gold-coated quartz crystals modified with the surface capture 
probe upon addition of increasing concentration (in pM) of (a) target oligonucleotide captured 
onto AuNPs, (b) target oligonucleotide not linked to AuNPs, (c) control oligonucleotide linked to 
AuNPs, and (d) the control not linked to AuNPs. B. Mass changes shown for (a) control and (b) 
target oligonucleotides (0.5 pM) with or without linking to AuNPs. Data shown are mean ± 
standard deviations represented by error bars for N = 3 replicates. Relative standard deviations 
(RSDs) for the control were 17% with no AuNPs and 22% with AuNPs linkage. The RSDs for 
the target were 11% (no AuNPs) and 7% (with AuNPs). 
The QCM showed a significant mass change when the crystal was exposed to MHOH, suggesting 
that this reagent has an efficient free surface blocking ability to minimize non-specific interactions. 
The AuNP bioconjugation with the target oligonucleotide amplified the mass changes by ~2.5 times 
in comparison to the hybridization signals without the AuNPs strategy (Fig. 4A–B). The small 
QCM signal responses for the control oligonucleotide suggest good selectivity and specificity for 
the surface capture probe to the target miRNA-21 mimic sequence. Even after linking with AuNPs, 
the responses were quite negligible in the control, which had five base pair mismatches relative to 
the target (~13 times less signal than the target). With the signal amplification strategy, we were 
able to detect the target concentrations from 0.05 to 50 pM. 
A B 
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4.3.3 Pixel intensity changes in the SPR microarray in response to target or control 
nucleotide hybridization with the surface capture probe. 
Selective hybridization of the target over the control oligonucleotide with the surface capture probe 
coated on the SPR gold microarray was observed, similar to the mass sensor results. Figure 5 shows 
the real-time response plots of the SPR imager. Measurements were made from the new steady 
state baseline observed after washing the microarray surface with phosphate-buffered saline (PBS) 
for 10 minutes, which was sufficient to remove bulk and unhybridized oligonucleotides in solution. 
 
 
 
 
 
 
 
  
Figure 5. Real-time SPR response (average of eight array spots) for the binding of 0.5 pM of (a) 
target or (b) control oligonucleotide linked with AuNPs onto the surface immobilized capture 
probes at a flow rate of 50 μL/min. Sample injection and buffer wash points are labeled. 
The blocking agent-treated SPR spots that contained only MHOH (Fig. 6) showed no nonspecific 
hybridization signals after exposure to the AuNP-linked target or control oligonucleotide. The dual-
channel SPR microarray allowed measurement of the pixel intensity changes with the simultaneous 
introduction of similar concentrations of the target and control oligonucleotides. The observed 
changes in the pixel intensities for various concentrations of AuNP-linked target oligonucleotides 
(0.1 – 50 pM) are summarized in Figure 6 as 3D image representations, and line profiles. These 
data show that the small gold spot array surface with about 0.008 cm2 of geometric area allows 
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sufficient immobilization of surface capture probe molecules to hybridize with the low 
concentration of target oligonucleotide.  
Figure 6. Representations of SPRi responses: the 3D representation (left) and the line profile (right) 
that depicts the SPR pixel intensities for various concentrations of target and control nucleotides. 
The spot labeled as (a) is the bare gold surface treated with 5 mM MHOH and that of (b) are the 
test spots containing the immobilized capture probes. (A)-b: control oligonucleotide of (i) 0.1, (ii) 
0.5, (iii) 1, (iv) 10, (v) 30, and (vi) 50 pM concentrations conjugated with AuNPs; and (B)-b: target 
oligonucleotide of concentrations similar to those of the control allowed to bind with the surface 
capture probe. 
 
The surface capture probe demonstrated excellent selectivity for the target oligonucleotide over the 
control oligonucleotide (with five base pair mismatches). The observed changes in the pixel 
intensities for the control spots were very low, illustrating that there was minimal non-specific 
interaction between the control oligonucleotide and the surface capture probe. The spots that were 
completely blocked with MHOH showed negligible non-specific binding to the target or the control 
oligonucleotide, suggesting no false-positive signals in the absence of the surface capture probe. 
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4.3.4 Comparison of QCM and SPRi methods 
QCM is an excellent quantitation method, and it can provide high sensitivity and selectivity with 
use of an appropriate signal amplification strategy and surface chemistry. Results described herein 
are similar to those of our prior demonstration of an electrochemical QCM immunosensor for serum 
insulin measurements based on magnetic nanoparticle conjugation.40 The double logarithmic 
response plot shown in Figure 7A shows a linear correlation (R2=0.99) between the mass change 
and concentration of the target oligonucleotide. The limit of detection (LOD)43,44 for QCM-based 
quantification was 28 fM, which is a promising detection level and indicates the uniqueness of the 
designed experimental conditions in achieving ultra-low detection resulting from minimal 
nonspecific and false-positive signals. 
Although the QCM method provides sensitivity, quantitative details, and is useful for optimization 
of assay conditions, it is a low throughput approach (i.e., one sample at a time, and the most 
commonly available form is single quartz crystals). This is because designing a QCM crystal array 
is challenging due to engineering difficulties arising from the need to control piezoelectric 
properties across the array.45,46 Better throughput can be achieved by using the SPR microarray 
strategy. The advantage of using the SPR microarray is that several concentrations can be studied 
on the same array platform without the need for multiple experiments. Thus, samples and controls 
can be analyzed in the same array in one experiment. Another advantage is that the required volume 
of samples is low (200 nL per SPR array spot are sufficient, whereas a QCM crystal needs several 
μL of sample). The use of AuNPs contributes to enhancement of the SPRi reflectivity changes due 
to the electronic coupling between the plasmons of AuNPs and that of the gold sensor surface upon 
hybridization of the nucleotides.47,48 The LOD for the SPRi method in this study was 47 fM. 
Although this LOD is slightly higher than that of QCM, our assay in a microarray format displays 
a better throughput and similar sensitivity (Fig. 7B). 
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Figure 7. Double logarithmic calibration plots of A. QCM response (control response is subtracted) 
and B. SPRi response (control response is subtracted) upon hybridization of various concentrations 
of the AuNP-conjugated target oligonucleotide with the surface capture probe. (mean ± standard 
deviation for three replicates). 
 
4.3.5 Assessment of selectivity 
A recovery test was performed to evaluate the efficiency of the QCM and the SPRi microarray in 
detecting the AuNP-linked target oligonucleotide marker prepared in various concentrations of 
human serum. Prior to conjugation with AuNPs, 1 pM of the target and control oligonucleotides 
were suspended in different concentrations of human serum (10, 25, 50, and 75%) diluted in PBS 
solution (pH 7.4). A protocol similar to that described under the Experimental methods was 
followed to prepare AuNP-linked target or control oligonucleotides. Table 3 presents the sample 
recovery results for analyzing serum samples. Recovery was calculated as a percentage from the 
fraction of spiked nucleotide concentration detected after subtracting the control signals. The SPR 
microarray offered a reasonably good recovery until 25% serum was reached (> 90%), whereas for 
the QCM sensor analyte recovery (> 90%) was significantly affected above 10% serum. The results 
obtained suggest the likely applicability of calibration plots generated from buffer nucleotide 
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standards for the determination of nucleotide concentrations present in 10 - 25% serum samples. A 
lower dilution factor for serum sample analysis is preferred, as it would minimize dilution of the 
nucleotide marker in serum and facilitate easier detection when applied to patient samples. 
Table 3. Analysis of the target oligonucleotide in different percentages of serum samples (diluted 
in PBS, pH 7.4) using the QCM and SPR microarray. 
Serum % [Actual] (pM) [Detected] from 
calibration (pM) 
Recovery 
(%) 
QCM 
10 1.00 0.93 93% 
25 1.00 0.82 82% 
50 1.00 0.76 76% 
75 1.00 0.67 67% 
SPR microarray 
10 1.00 0.95 95% 
25 1.00 0.93 93% 
50 1.00 0.84 84% 
75 1.00 0.64 64% 
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Table 4 provides a short comparative summary of previous studies that measured various nucleic acids using AuNPs as a source of signal 
amplification. Our SPR microarray (LOD: 47 fM) and QCM (LOD: 28 fM) results are better than or comparable with the detection levels 
reported in prior studies. 
Table 4. Summary of recent studies related to nucleic acid detection. 
Technique Tested molecules Sample matrix Detection limit Ref. 
Multiplexed miRNA detection using 
AuNP-modified poly-T DNA 
hybridization SPR microarray 
 
miRNA-16, miRNA- 
122b, miRNA-23b 
0.3 M NaCl/ 10 mM 
phosphate buffer (pH 7.4) 
10 fM Fang et al., 
200649  
DNA sensing using catalytic growth of 
AuNP-enhanced SPR 
 
cDNA, ssDNA 0.3 M NaCl/ 10 mM 
phosphate buffer (pH 7.0) 
4.8 pM Yang et al., 
200750  
AuNP-amplified SPR interfaces for the 
detection of mercury ions using hairpin 
DNA probes containing a 21mer T-
rich Hg2+ binding sequence loop 
 
Hairpin DNA TE buffer (10 mM Tris–
HCl, 50 mM 
NaCl, 1 mM EDTA, pH 
8) 
1 nM Chang et al., 
201151  
Label free multiplexed detection of 
miRNA using silicon photonic 
microring resonator arrays 
 
miRNA-24-1 PBS 
 
 
 
 
 
150 fM Qavi et al., 
201052  
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Nanopore-based programmable 
oligonucleotide probe for circulating 
miRNA quantification 
 
miRNA-155 1 M KCl buffered with 10 
mM Tris (pH 8.0) 
100 fM Wang et al., 
201153  
Gold nanoprism based localized SPR 
sensor for miRNA detection  
 
miRNA-21, miRNA-
10b 
PBS buffer (pH 7.4) and 
40% human plasma 
50 fM Joshi et al., 
201454  
3D tetrahedral DNA nanostructure for 
DNA recognition and amplification by 
hybridization chain reaction using 
QCM 
 
Synthetic DNA targets TM buffer (10 
mM Tris-HCl and 50 mM 
MgCl2, pH 8.0) 
0.1fM Ge et al., 
201455  
Carboxy-polyethylene glycol 
microarray for AuNP-based detection 
of miRNA using differential 
interference contrast microscopy 
 
let-7a 
let-7b 
let-7f 
let-7g 
Saline sodium citrate  10 fM Roy et al., 
201656  
Mass sensor 
 
SPR microarray 
 
miRNA-21 mimic Phosphate buffer (pH 7.4) 28 fM 
 
47 fM 
This study 
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4.4 Conclusions 
We have designed highly sensitive sensors that provide a platform for detecting specific 
oligonucelotide biomarkers at femtomolar levels by linking them with AuNPs to enhance 
plasmonic sensitivity. The SPR microarray offers better throughput with a comparable LOD than 
a QCM sensor provides. Compared to the QCM sensor, the SPR microarray allows multiple 
experiments to be run with suitable controls using the dual-channel syringe pump system, 
minimizing assay time and offering improved precision. Thus, the SPR microarray approach is 
promising for clinical applications to accomplish early diagnosis, treatment, and monitoring of 
recurrence of diseases based on circulating miRNAs as biomarkers.  
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CHAPTER 5   
 
 
MULTIPLEXED SURFACE PLASMON ASSAY FOR SERUM PROTEINS AND MICRO-
RIBONUCLEIC ACIDS: SIGNAL AMPLIFICATION BY BIMETALLIC Fe3O4@Au 
NANOPARTICLES   
5.1 Introduction 
To increase prediction rates by reducing false positive diagnoses based conventionally on a single 
marker analysis, it is important to measure a panel of key biomarkers. Highly expressed circulating 
protein and micro-ribonucleic acids (miRNA) markers have received increased attention in liquid 
biopsy studies due to their promising predictability feature.1 Many analytical methods including 
enzyme-linked immunosorbent assay (ELISA), spectroscopic and molecular biology techniques 
(real-time polymerase chain reaction, northern blotting, microarray technology, and in situ 
hybridization) have been employed in cancer biomarker detection.2,3  
In view of developing molecular technologies that enable more precise and objective decision 
making, surface plasmon resonance (SPR) spectroscopy with multiplexed imaging integrated with 
the advances in microfluidics is an attractive strategy. SPR is a highly sensitive surface analysis 
technique that can determine the binding events of various ligands to their respective receptors 
through refractive index changes.4,5 Additionally, SPR can be used for high-throughput screening 
and to obtain real-time binding insights of biomolecular interactions by elegantly tuning the surface 
chemistries and metal-dielectric interfacial properties.6-8 Due to these features, SPR methods have 
been widely employed for selective detection of various biomarkers.9-11
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Incorporation of nanomaterials in bioassays offers the unique advantages of robustness due to 
superior chemical and solvent stability compared to light-sensitive labels, versatility to be adopted 
to various analytical techniques, and increased sensitivity and lowered detection limits. However, 
the compromise on the linear dynamic range for high sensitivity needs to be overcome for 
nanomaterial-based assays to measure various analyte concentrations in clinical samples.12,13 
Among metal nanoparticles (NPs), the bimetallic NPs allow tuning of plasmonic and magnetic 
properties, and the core (inner component)/shell (outer component) class is one of the important 
types that combine the beneficial properties of the two different nanomaterials.14,15  Different 
bimetallic combinations such as silver@gold, iron@platinum, platinum@cobalt, and 
gold@platinum have been designed for biosensing, bio-imaging, and drug delivery applications.16 
In particular, the magnetic properties of the iron-gold (Fe3O4@Au) bimetallic NPs offers the dual 
benefit of (i) easy conjugation and magnetic separation of desired compounds for subsequent 
detection in the assay;17 and (ii) the plasmonic gold shell properties are useful for amplifying the 
surface plasmon detection signals.18 In addition, the coating of Fe3O4 NPs with a gold material 
provides more dispersibility and room for various surface functionalization strategies (e.g., thiols, 
polymers, small molecules, dendrimers) for immobilizing biomolecules.19,20 Brown et al. 
demonstrated the synthesis of homogeneous and larger NPs via a seeding method involving the 
reduction of gold salts by using either sodium citrate or hydroxylamine reagents.21  Pham et al. 
magnetically separated IgG protein by gold-coated Fe3O4 NPs of 15-40 nm size.17  
In this report, for the first time, we have devised a multiplexed SPR imager (SPRi) microarray 
utilizing Fe3O4@Au NPs to simultaneously measure two protein and two miRNA markers present 
in human serum. Greater plasmon enhancement signal in the imager by the synthesized Fe3O4@Au 
NPs over either Fe3O4 or Au NPs of similar sizes is demonstrated. To demonstrate the applicability 
of our SPRi bimetallic NP-based assay for health monitoring based on circulating biomarkers, we 
chose two interleukins (IL-6 and IL-8) and miRNAs (miRNA-21 and miRNA-155) as 
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representative biomolecules. These markers were detected by spiking them in 10% normal human 
serum. 
IL-6 has been reported to be one of the major cytokines found in the tumor microenvironment and 
in the circulatory system, and it is found to be over-expressed in all types of tumors depicting their 
progression and severity.22 At the same time, the serum concentration of IL-8 has been found to 
correlate with tumor burden, thus making it a useful pharmacodynamic-biomarker to detect 
responses to cancer immunotherapy.23 Among the members of the miRNA family, miRNA-21 is 
one of the consistently upregulated circulatory biomarkers in cancer patients.24  Similarly, the 
miRNA-155 is a robust oncogenic circulating miRNA, and its overexpression can indicate the 
promotion of tumorigenesis.25 The circulating concentrations of miRNA-21 and miRNA-155 
markers have the potential utility for early diagnosis and monitoring of tumors as well as for 
predicting chemoresistance.  
Fe3O4@Au bimetallic NPs are employed as a signal amplification label on the SPRi platform to 
increase sensitivity and mitigate the responses arising from the non-specific interaction of other 
components in a serum sample. The designed sensor not only detects four biomarkers, but also 
offers kinetic information, which is vital to understanding the degree of interaction of the chosen 
receptors with the target analytes, and the analytical advantage of the designed assay strategy. Such 
an SPRi array platform represents a useful bioassay that can be well adapted for analysis of 
biomarkers present in clinical samples.  
5.2 Experimental  
5.2.1 Materials and chemicals 
Thiol modified custom-designed DNA oligonucleotides and miRNAs (sequences presented in 
Table 1), bovine serum albumin (BSA), dithiothreitol (DTT), 6-mercaptohexanol (MHOH), 3-
mercaptopropionic acid (MPA), ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
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(EDC), and N-hydroxysuccinimide (NHS), gold(III) chloride trihydrate (HAuCl4.3H2O), sodium 
borohydride, sodium citrate, gold and iron standards for ICP analysis (1000 ppm) were obtained 
from Sigma-Aldrich (St. Louis, MO). Recombinant IL-6 and IL-8 proteins, and purified anti-human 
IL-6 and IL-8 sandwich antibodies (the surface-immobilized antibody is monoclonal and the 
bimetallic NP-attached detection antibody is polyclonal) were purchased from BioLegend Inc., 
(San Diego, CA). The human serum samples were purchased from Fitzgerald Industries 
International Inc., (North Acton, MA). Citrate-stabilized magnetic nanoparticles (Fe3O4 NPs, 50 
nm hydrodynamic diameter) were purchased from Chemicell GmbH Inc., (Berlin, Germany). 
Ultrapure deionized water (DI water) and NAP-10 columns were obtained from GE Healthcare 
(Cranbury, NJ). SpotReady-16 gold spotted glass microarray chips (spot size 1 mm diameter, SPR-
1000-016) were obtained from GWC Technologies (Madison, WI). 
Table 1. Sequences of the custom-designed DNA oligonucleotides employed in this study. (In the 
hairpin capture DNA, the sequences in italics (underlined) are complementarity to the target 
miRNA sequence, the sequences in bold are the hairpin forming sequence, and those highlighted 
in gray are complementary to the sequence of the bimetallic NPs attached detection DNA. The 
detection DNA partially hybridizes with the exposed region of the hairpin surface DNA when pre-
hybridized with the miRNA marker) 
 
 
 
 
miRNA-21 5'UAGCUUAUCAGACUGAUGUUGA3' 
Hairpin capture DNA 
for miRNA-21 
5'SH-(CH2)6-
ATTGAATCGAGTCAACATCAGTCTGATAAGCTATGCATAGCTTC
AAT-(CH2)3-NH23' 
miRNA-155 5'UUAAUGCUAAUCGUGAUAGGGGU3' 
Hairpin capture DNA of 
miRNA-155 
5'SH-(CH2)6-
ATTGAATCGAGACCCCTATCACGATTAGCATTAATGCATAGCTTC
AAT-(CH2)3-NH23' 
Detection DNA        
(Fe3O4@Au NP bound)   
5'SH-(CH2)3–TTTTTTTTTTTTTGATTGAAGCAT3' 
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5.2.2 Instrumentation 
The optical measurements were made using a SPRimagerII array instrument at room temperature 
(Horizon SPR imager model) operating at a SPR source wavelength of 800 nm (GWC 
Technologies, Madison, WI, USA). The experiments were conducted using our custom designed 
four channel microfluidics set-up, each connected to a syringe pump (100 µL sample loop, New 
Era Pump System, Inc., NY, USA). The SPRi pixel intensities for increased miRNA or IL 
concentrations upon binding to their surface-immobilized selective receptors followed by signal 
amplification from the binding of Fe3O4@Au NPs linked detection probes were measured. Digital 
Optics V++ software package provided in the instrument was used to collect the SPRi difference 
images (i.e., differences of the pixel intensities before and after the binding events), and the 3D-
images were represented using ImageJ 1.49v software (NIH, USA).  
Quantification of oligonucleotides was done by a Nanodrop ND1000 spectrophotometer (Thermo 
Scientific, Waltham, MA). The UV-vis spectral absorbance of antibodies and DNA 
oligonucleotides was measured at 280 and 260 nm, respectively.26 The elemental analysis of the 
Fe3O4@Au NPs was performed by an inductively coupled plasma optical emission 
spectrophotometric analyzer (ICP-OES, SPECTRO Analytical Instruments Inc., NJ, USA). The 
emission line selected for the Fe was 259.9 nm, and for Au, the line was 267.5 nm.27  
 Transmission electron microscopy (TEM, JEOL JEM-2100) images of the synthesized Fe3O4@Au 
NPs were obtained by preparing drop-coated samples on carbon surface grids. Surface 
characterization of the gold microarray before and after coating with the surface capture DNA, after 
hybridizing with the miRNA marker, and subsequently, with the plasmon enhancing Fe3O4@Au 
NPs linked detection probes was conducted by scanning electron microscopy (SEM, Model: FEI 
Quanta 600FE). An accelerating voltage of 20 kV was applied. The images were acquired using 
the FEIxT Microscope Control Software. The hydrodynamic diameter and surface charges of 
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Fe3O4@Au NPs covalently attached with the detection antibody or DNA were measured using a 
ZetaPALS potential analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA). 
5.2.3 Synthesis and characterization of Fe3O4@Au bimetallic nanoparticles 
By adopting a seed growth technique derived from the process called Ostwald ripening, gold NPs 
coated onto Fe3O4 NPs were synthesized (Figure 1).28 During this process, the continuous growth 
of the gold layer will take place on the surface of Fe3O4 NPs. This will cause the bimetallic NPs to 
significantly grow in size. A reaction flask containing HAuCl4.3H2O (10.3 mg/mL, 5 mL), sodium 
citrate (59.3 mg/mL, 5 mL), Fe3O4 NPs (25 mg/mL, 0.5 mL) and 25 mL of H2O was refluxed at 
100 oC for 10 min. A freshly prepared mixture of HAuCl4.3H2O (4.53 mg/mL, 10 mL), Fe3O4 NPs 
(0.12 mg/mL, 10 mL), and sodium citrate (22.55 mg/mL, 10 mL) was then added to the reaction 
flask as 1 mL aliquots for every 2 min at 90 oC. This secondary addition of the reaction mixture 
controls the size of the outer Au shell formed around the Fe3O4 NPs. 
 Synthesized nanoparticles were characterized to determine their physical and chemical properties. 
The Fe3O4@Au NPs were compared with similarly sized Au NPs or Fe3O4 NPs to estimate the 
relative SPRi signal enhancement property. 
 
 
 
 
 
 
Figure 1. Schematic illustration of the synthesis of Fe3O4@Au bimetallic NPs using the reaction 
mixture consisting of 1. HAuCl4.3H2O, 2. Fe3O4 NPs, and 3. sodium citrate. 
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5.2.4 Preparation of the covalent conjugates of Fe3O4@Au NPs with detection antibodies 
The surface lysine residues of IL-6 and IL-8 second antibodies were attached to the carboxylic acid 
groups of citrate molecules adsorbed around Fe3O4@Au NPs using a protocol employed in our 
previously reported studies.29-31 Briefly, the Fe3O4@Au NPs were suspended in freshly prepared 
aqueous solution containing EDC (0.35 M) and NHS (0.1 M) and allowed to incubate for 20 min 
to create the easily leaving N-succinimidyl ester units of the carboxyl groups. The NPs were 
separated magnetically by using a magnet to remove the unreacted EDC/NHS solution. The 
particles were then washed twice with phosphate buffered saline (PBS), magnetically separated 
after each wash, and resuspended in PBS (pH 7.4). A freshly prepared antibody solution (200 μL 
of 5 µg mL−1 in pH 7.4 phosphate buffer) was immediately added to the NP solution. The covalent 
attachment of antibodies to NPs was carried out for 1 h at room temperature with a continuous 
gentle mixing of the reaction tubes in an incubator (Labnet International Inc.,). Covalently attached 
Antibody-Fe3O4@Au conjugates were separated from the free antibody solution by the magnet and 
the conjugates were washed twice in PBS, resuspended in a 200 μL of a fresh PBS solution before 
using for SPR studies.  
5.2.5 Preparation of the conjugates of Fe3O4@Au with detection DNA molecules 
Initially, to prepare the DNA oligonucleotide linked to Fe3O4@Au NPs, a protocol provided by the 
manufacturer (Sigma-Aldrich) was followed to reduce the disulfide-modified oligonucleotide for 
thiol-activation. For this, the dry oligonucleotide sample was treated with an aqueous solution of 
DTT (100 mM) at 10:1 ratio (µL DTT to A260 units of oligonucleotides) and incubated for 1 h at 
room temperature. A NAP-10 column, pre-equilibrated with approximately 15 mL of 50 mM 
sodium phosphate buffer (pH 6.0), was used to remove DTT and any other irrelevant impurities. 
The concentration of the purified detection oligonucleotide was determined by measuring 
absorbance at 260 nm using a NanoDrop spectrophotometer (1 mm path length light source; CCD 
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array detector) and the molar extinction coefficient of the detection oligonucleotide sequence 
(εdetection: 227.8 mM-1cm-1, Sigma-Aldrich).  
DNA-Fe3O4@Au conjugates were prepared by chemisorbing the thiol-activated oligonucleotides 
according to our previously described method with slight modifications.32 In short, 500 µL of 2 µM 
detection DNA oligonucleotide solution prepared in sodium phosphate buffer (pH 6.0) was mixed 
with 250 µL of Fe3O4@Au solution and incubated with gentle mixing for 4 h at 37 oC. Upon 
completion of incubation, 250 µL of 1 M NaCl/0.1 M sodium phosphate buffer (pH 7.4) and 500 
µL of distilled water were added and incubated for 24 h at 37 oC. The high salt 1 M NaCl/0.1 M 
sodium phosphate buffer (pH 7.4) solution favors the thiolated DNA to adsorb well on to the gold 
surface of Fe3O4@Au NPs.33 Following this, the DNA-Fe3O4@Au conjugates were magnetically 
separated from the supernatant and were rinsed twice with 0.3 M NaCl/0.1 M sodium phosphate 
buffer (pH 7.4) and brought to the original volume of 500 µL with PBS (pH 7.4), prior to use in the 
assay. The low salt 0.3 M NaCl/0.1 M sodium phosphate buffer (pH 7.4) prevents the irreversible 
growth of the Fe3O4@Au NPs after linking to DNA.33  
5.2.6 Preparation of the four-channel microarray and multiplexed analysis  
Eight spots on the SPRi gold array chip were incubated in 100 mM of MPA solution in ethanol for 
12 h to form a self-assembled monolayer with free carboxyl surface groups. The chip was then 
washed thoroughly with DI water and dried under nitrogen. Following the EDC/NHS activation, 
the spots were rinsed with DI water and air-dried. The capture antibody of IL-6 or IL-8 (0.25 µL 
of 1 µg mL-1 per spot) was placed on four spots of the gold array. Similarly, the thiol-activated 
hairpin capture DNA of miRNA-21 or miRNA-155 (0.25 µL of 1 µM solution per spot) was placed 
on four spots of the gold array.  
The capture molecules were immobilized for a duration of 1 h in a moist, cold environment (4 oC, 
Figure 2). The free surface of the oligonucleotide-coated spots was blocked using 5 mM MHOH 
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for 30 min and the chip was washed with PBS (pH 7.4) to minimize non-specific binding 
interactions. 
  
 
 
 
 
 
 
 
 
Figure 2. A. The experimental set-up for multiplexed SPRi analysis using a four-channel flow 
injection system. B. The SPRi chip was modified with capture probes (CAb: capture antibodies or 
CDNA: capture DNA) and the analytes were assayed as follows: Two lanes (4 spots each) of the 
SPRi microarray were self-assembled with a monolayer of MPA. The remaining two lanes were 
self-assembled with thiol-activated hairpin capture DNAs of miRNA-21 and miRNA-155 (4 spots 
each) followed by blocking the free surface with MHOH. The IL-6 and IL-8 capture antibodies 
were covalently attached to the -COOH activated MPA surface (4 spots each) followed by blocking 
of the free surface with 1% BSA. Various concentrations of the protein and miRNA markers were 
spiked in 10% human serum and allowed to bind their respective capture molecules on the chip 
using the designated individual flow channels. The signal amplification step of the bioassay was 
subsequently followed by introducing the respective detection molecules (DAb: detection antibodies 
or DDNA: detection DNA) conjugated to Fe3O4@Au NPs yielding detection DNA-Fe3O4@Au or 
detection antibody-Fe3O4@Au NPs. 
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The modified chip was immediately assembled on to the SPRi four-channel flow system with a 
layer of index matching fluid between the free glass side of the chip that will be in contact with the 
prism (Cargille Labs, NJ, USA). Each channel was connected to a sample injector unit and a syringe 
pump. Real-time measurements were performed using the running buffer, PBS (pH 7.4). 
Initially, the running buffer was pumped at a flow rate of 50 µL min-1, and a reference image of the 
array was taken at first. The sample injector loops (100 μL volume) were then separately filled with 
known concentrations of IL-6, IL-8, miRNA-21, or miRNA-155 solutions spiked in 10% normal 
human serum in PBS (pH 7.4), and allowed to pass onto the capture molecule modified arrays for 
45 min. Upon completion of the incubation, the chip surface was washed for 10 min with the 
running buffer to remove all unbound molecules. Then 100 μL of Fe3O4@Au NPs conjugated to 
detection molecules were introduced and incubated for 30 min, and washed with running buffer for 
10 min before measuring the net pixel intensity changes. A control experiment was conducted by 
treating the capture probe-modified microarray with only 10% serum to obtain the background 
signals. 
The final images of the microarray were acquired using a CCD camera. The difference images 
taken before and after each assay step are represented in a 3D format using ImageJ software (1.49v, 
NIH, USA). Multiplexing provided room for the analysis of four biomarkers in a single assay and 
minimized multiple experiments due to the microarray platform. 
5.3 Results and Discussion  
5.3.1  Hydrodynamic size and zeta potential of Fe3O4@Au NPs and conjugates 
The average hydrodynamic diameter of the synthesized Fe3O4@Au NPs and its conjugates with the 
detection molecules (second antibody or oligonucleotide) were determined by the dynamic light 
scattering (DLS) method (Table 2). A total of five measurements were made at a 90o angle (2 min 
per measurement). The samples were diluted five times prior to measurements in PBS (pH 7.4). 
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The antibodies contain free surface lysine residues to covalently attach them to the surface carboxyl 
groups on Fe3O4@Au NPs with random orientations, and no additional steps were implemented for 
orienting the antibodies.34  
The average size of the Fe3O4@Au NPs increased by about 25 nm after the antibody attachment. 
This is consistent with the typical hydrodynamic size of the antibodies (10 to 15 nm).35 A similar 
size increment was observed upon chemisorption of thiol-activated DNA to the Fe3O4@Au NPs. 
The polydispersity index was ≤ 0.2 indicating good dispersion and narrow size distributions of the 
conjugated NPs in the buffer medium, which is likely the result of surface charge repulsions. 
Table 2. The hydrodynamic diameters and ζ-potentials of Fe3O4@Au NPs and their conjugates 
with a detection antibody (shown here for IL-6 second antibody) or a detection DNA probe.  
Parameter  Fe3O4@Au NPs Antibody-Fe3O4@Au  DNA-Fe3O4@Au  
Hydrodynamic 
diameter (nm) 
105 ± 6 132 ± 11 124 ± 5 
Polydispersity index 0.19 ± 0.03 0.18 ± 0.05 0.15 ± 0.01 
ζ potential (mV) -38 ± 4 -12 ± 1 -51 ± 3 
 
The ζ-potential was calculated by phase analysis of light scattering (PALS) that determined the 
electrophoretic mobility of the particles by Smoluchowski's equation available with the instrument 
software. Diluted samples were used to measure the ζ-potential of the NPs and conjugates for a 
total of 10 measurements with each measurement lasting for 30 seconds (Table 2). The negative ζ-
potential measured for the unconjugated NPs is due to the citrate surface groups. The anti-IL 
antibodies are members of an IgG class and they typically bear an isoelectric point (pI) of 8-9.536 
and hence a net positive charge at pH 7.4. This is in agreement with the significant shift in the 
positive ζ-potential for the detection antibody attached Fe3O4@Au NPs. The intrinsic negative 
charge of nucleotides37 due to their phosphate groups shifted the ζ-potential of Fe3O4@Au NPs to 
more negative values (Table 2). 
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5.3.2 Elemental composition of the Fe3O4@Au NPs 
One mL of a solution of Fe3O4@Au NPs (3 mg/mL) was digested for 4 h in 9 mL of HNO3:HCl 
(1:3) acid mixture in a hot-water bath.38 Upon completion of the digestion, the samples were diluted 
to 25 mL volume with deionized water. The Fe and Au standard solutions (0.5 to 100 ppm) were 
prepared by diluting the stock solutions (1000 ppm) in DI water. A calibration curve was developed 
using the standard solutions prior to analyzing the digested Fe3O4@Au NPs nanoparticle samples 
(N = 3). The percentage composition of Fe and Au was found to be 21.5 ± 0.4 ppm (91%) and 2.1 
± 0.1 ppm (9%), respectively. 
5.3.3 Estimation of SPRi signal amplification by Fe3O4@Au NPs over Fe3O4 or Au NPs of 
similar sizes 
To determine the SPRi signal amplification, the pixel intensities of Fe3O4 NPs (100 nm), Au NPs 
(100 nm), and the synthesized Fe3O4@Au NPs (75 nm) or Fe3O4@Au NPs (105 nm) were 
compared, similar to that reported previously.39 In brief, the SPRi microarray was coated with a 
polycationic layer, polyethyleneimine (PEI, 0.1 mg mL-1 in DI water), by adsorbing for 30 min, and 
washed with DI water. The negatively charged citrate-stabilized NPs were then adsorbed for 30 
min on the polymer coated spots and rinsed with DI water to remove any unbound NPs. The 
difference image obtained (before and after the coating with NPs) was processed by ImageJ 
software to obtain 3D representations (Figure 3).  
The pixel intensities for the synthesized Fe3O4@Au NPs (75 nm) were 9-times and 4-times higher 
than Fe3O4 (100 nm) NPs and Au NPs (100 nm) alone, respectively. The increase in the Au shell 
size in the case of 105 nm Fe3O4@Au NPs further increased the SPRi pixel intensity to ~ 11-times 
and 6-times over the  Fe3O4 (100 nm) and Au NPs (100 nm) alone, respectively. This could be 
attributed to the spectral overlap of the surface plasmon resonance in the Au shell with an intrinsic 
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electronic transition with the Fe3O4 core.18 The results provide evidence for the Au shell containing 
bimetallic NPs for enhancing the plasmon resonance. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The SPRi responses of A. 100 nm Fe3O4 NPs, B. 75 nm Fe3O4@Au NPs, C. 100 nm Au 
NPs, and D. 105 nm Fe3O4@Au NPs adsorbed onto 0.1 mg mL-1 PEI coated gold surface. (a) 
Schematic and experimental 3D images of SPR pixel intensity, (b) only the PEI adsorbed gold 
surface. The corresponding line profiles and difference images (in grey) are shown on the right. 
 
5.3.4 Microscopic characterization of the NPs and surface binding event of the conjugates 
made with detection probes 
Figure 4A represents the TEM image of synthesized Fe3O4@Au NPs. The particles assumed nearly 
a spherical shape with an observable lighter Au layer around the darker Fe3O4 centers. The smaller 
size observed compared to the hydrodynamic diameter is due to the dried samples under the high 
vacuum conditions applied in the electron microscopic imaging.29 Figures 4B to 4D are the SEM 
images obtained for the smooth gold surface of the microarray, the capture 
antibody/antigen/detection antibody-Fe3O4@Au NP complex for IL-6 protein, and the hairpin 
capture DNA /miRNA/detection DNA-Fe3O4@Au NP complex of miRNA-155, respectively. 
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Figure 4. TEM image of A. Fe3O4@Au NPs. SEM images of B. bare Au surface of the microarray, 
C. IL-6 capture antibody/IL-6/Fe3O4@Au NP-IL-6 detection antibody assembly, and D. miRNA-
155 capture DNA/miRNA-155/Fe3O4@Au NP-miRNA-155 detection DNA assembly. 
5.3.5 Quantitation of capture and detection molecules used in the designed SPRi microarray 
for multiplexed detection of miRNAs and ILs 
The fabricated microarray followed the sandwich type immunoassay strategy for IL detection and 
a dual hybridization of the hairpin capture DNA for selectively capturing the target miRNA marker 
from serum and detection with Fe3O4@Au NPs carrying the detection nucleotide. The 
spectrophotometric quantification of the amount of capture DNA self-assembled on the microarray 
surface and the number of detection probes attached to Fe3O4@Au NPs is presented in Table 3. 
This quantitation confirmed the successful immobilization on the desired surfaces. 
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Table 3. The quantitation of capture molecules immobilized on the microarray and detection 
molecules conjugated to the Fe3O4@Au NPs. 
 
5.3.6 Real-time analysis of serum biomarkers 
The real-time sensograms, difference images, 3-D representations, and line profiles corresponding 
to the multiplexed detection of ILs and miRNAs spiked in 10% human serum are presented in 
Figure 5. The detection probes conjugated to Fe3O4@Au NPs increased the SPRi responses by 
about 2-fold for the ILs and 8-times for the miRNAs. This can be attributed to the additional 
selective biological interaction and the NP-induced plasmon signal enhancements. 
Figure 6 presents the linear response plots of SPRi signals subtracted for the signals resulted from 
the control serum sample.  An increase in the SPRi responses for increased concentration of 
analytes spiked in to the serum confirms the specificity of the surface capture probes towards the 
target analytes of interest. IL-6 and IL-8 demonstrated a linearity from 20 pM – 100 nM and 10 pM 
Molecules used for 
conjugation 
Amount of 
molecules added 
(pmol) 
Amount of 
molecules 
attached  (pmol) 
Average 
immobilization 
efficiency (%) 
Surface 
immobilized 
biomarker 
capture 
molecules 
IL-6 capture 
antibody 
0.013 ± 0.002 0.008 ± 0.001 61 ± 10 
IL-8 capture 
antibody 
0.013 ± 0.002 0.008 ± 0.002 60 ± 11 
miRNA-21 
capture DNA 
200 ± 38 155 ± 18 77 ± 17 
miRNA-155 
capture DNA 
200 ± 30 158 ± 15 79 ± 14  
 
Fe3O4@Au 
NPs 
IL-6 detection 
antibody 
16.6 ± 3.5 12.3 ± 1.8 74 ± 18 
IL-8 detection 
antibody 
16.7 ± 2.3 11.8 ± 1.5 71 ± 13 
miRNA-21/155 
detection DNA 
1000 ± 118 817 ± 52 82 ± 11 
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– 75 nM (~104 orders of magnitude), respectively. A wider dynamic range was observed for 
miRNA-21 and miRNA-155 from 50 fM – 2 nM and 25 fM – 4 nM (~108 orders of magnitud), 
respectively 
Figure 5. SPRi responses for a multiplexed assay by the 4-channel flow injection analysis A. Real-
time pixel intensity changes for 10% serum spiked with a. IL-8 (10 nM), b. IL-6 (10 nM), c. 
miRNA-21 (0.25 nM), and d. miRNA-155 (0.25 nM). I. Represents the introduction of the 10% 
serum spiked with the markers to the capture probe coated microarray and II. represents the 
introduction of the detection probes conjugated to Fe3O4@Au NPs. B. Final difference image of 
the test spots after detection of protein and miRNA markers in a single microarray. C and D. 
Corresponding 3-D representation and line profile, respectively. 
The observed differences in the dynamic range may be due to variations in the functionalization of 
the SPRi chip with capture probes and the sizes of the markers. The smaller self-assembled 
monolayer of capture miRNAs can be immobilized at greater densities than the larger antibodies 
of ILs. Thus, the sensitivities of miRNA detection were ~ 4-times greater than those for the ILs. 
Additionally, the hairpin capture DNA probes consist of a stem-loop oligomer structure that is 
structurally constrained, which thermodynamically increases the specificity of the target miRNA 
compared to a linear DNA probe.40  The hairpin opens up only in the presence of the target to form 
a duplex with the highly specific complementary nucleotide sequence present in the loop. The 
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hairpin DNA probes can recognize nucleotide targets even with a single-nucleotide 
polymorphism.41 
Figure 6. SPRi calibration plots for A. protein markers (IL-6 and IL-8) and B. miRNA markers 
(miRNA-21 and miRNA-155) in 10% human serum. (N = 3 replicates). 
The detection limits (DLs) for miRNAs and ILs were calculated by the following equation: DL = 
3 x standard deviation of the control/slope of the regression line. The DLs for IL-6, IL-8, miRNA-
21, and miRNA-155 were 28 pM, 18 pM, 502 fM, and 483 fM, respectively. These DLs and 
dynamic ranges were compared to those of other recent SPR assays that detected protein or miRNA 
biomarkers in various matrices using different amplification strategies (Table 4). Our methodology 
is unique in quantifying the serum protein and miRNA biomarkers through a multiplexed detection 
format. The higher DLs resulted when measurements are carried out in serum medium over a simple 
buffer solution can be understood from Table 4 data for miRNAs and proteins. 
5.3.7 Analysis of binding strength of protein and miRNA markers 
Determining binding kinetics is an important parameter to assess the strength of inteactions 
between the markers and their receptors on the designed assay surface. Additionally, we can use 
the binding constants as the quality control parameter to reproducibly make and use the bioassays 
for reliable large-scale applications.  
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The Langmuir adsorption isotherm was followed to determine the equilibrium dissociation kinetics 
based on a 1:1 bimolecular interaction model,42 where T is the target biomolecule and P is the 
surface capture probe involving the following binding event forming the complex, TP (eq 1): 
T + P 
𝑘𝑎
⇌
𝑘𝑑
 TP   (1)  
If Γ is the surface concentration of the TP complex and Γ𝑚𝑎𝑥 is the total concentration of binding 
sites available on the surface for the biomarkers, the adsorption (ka) and desorption (kd) kinetics can 
be described by eq 2, 
dθ
dt
 =  𝑘𝑎(1 − 𝜃)[𝑇] − 𝑘𝑑𝜃                (2) 
At equilibrium, the relative surface coverage (θ = Γ/Γ𝑚𝑎𝑥) reaches a steady state (dθ/dt = 0), and θ 
can be expressed by eq 3, 
 θ = 
KadsC
1+ KadsC
  
                           (3) 
Γ𝑚𝑎𝑥 can be related to the maximum signal upon saturating all the binding sites of the surface 
capture probes. C is the concentration of biomarkers and Kads is the Langmuir adsorption coefficient 
(Kads = ka/kd).  
Figure 7 shows the plots of relative surface coverage (θ) plotted against the tested concentrations 
of each biomarker. The data points were fit to a Langmuir isotherm (eq. 2) using OriginPro 2015 
software (Originlab, Northampton, MA). The difference in the shapes of the Langmuir isotherms 
for ILs and miRNAs can be due to the variations in their association rates.43 The Kads values obtained 
for IL-6, IL-8, miRNA-21, and miRNA-55 were 2.50 (± 0.17) x 107 M-1, 6.10 (± 1.08) x 107 M-1, 
7.00 (± 0.76) x 108 M-1 and 7.47 (± 1.10) x 108 M-1, respectively. At a bulk concentration equal to 
1/Kads, the concentrations of capture probes at 50% surface coverage (Cθ0.5) were determined. We 
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found Cθ0.5 values of 40.1, 22.4, 1.4, and 1.2 nM for IL-6, IL-8, miRNA-21, and miRNA-155, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Representative plots of the relative surface coverage (θ) as a function of the concertation 
of A. IL-6, B. IL-8, C. miRNA-21, and D. miRNA-155. The solid line represents the Langmuir 
isotherm fit to the data. All measurements were made in triplicates. 
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   Table 4. Detection performance comparison of our method with other SPR methods. 
Analyte  Matrix used for             
calibration 
Surface         
receptor 
Amplification 
method 
Dynamic range Detection limit 
 
Ref 
IL-8 Cellular elements 
removed saliva  
Anti-IL-8 
antibody  
Monoclonal second 
antibody  
9.5 - 191 pM (in 
buffer) 
 
184 pM 44 
Thrombin  20 mM HEPES 
buffer (pH 7.4) 
DNA-aptamer  Different shapes of 
Au NPs 
Up to 200 nM 
 
Cages:1 fM  
Rods:10 aM  
Quasi-spheres:1 
aM 
 
45 
C-reactive 
protein 
(CRP) 
1% human serum in 
diluted in 10 mM 
Tris, 15 mM NaCl 
and 2 mM CaCl2 
(pH 7.4) 
 
biotinylated 
aptamers 
CRP-Specific 
Aptamer reacted 
with Quantum dots 
5 – 5000 fg mL-1 5 fg mL-1 10 
miRNA-21 10 mM PBS (pH 
7.4)  
 
Stem-loop DNA AuNPs and DNA 
supersandwich* 
- 8 fM 46 
127 
 
miRNA-15a 0.1 M PBS (pH 7.0) Hairpin capture 
DNA 
Orthogonal signal 
amplification 
5 fM - 0.5 nM 0.5 fM 47 
miRNA-21 10 mM PBS (pH 
7.4) 
 
Stem-loop  
DNA 
Ag NPs adsorbed to 
DNA 
supersandwich* on 
DNA-linked AuNPs 
 
- 0.6 fM 48 
miRNA-141 10 mM PBS (pH 
7.4) 
DNA 
oligonucleotide  
DNA-linked 
AuNPs-MoS2 
Nanocomposite 
 
- 0.5 fM 49 
Insulin 
glucagon 
somatostatin 
PBS 
 
Insulin 
glucagon 
somatostatin 
antigens 
Direct binding of 
antibodies to their 
respective antigens 
Insulin: 34 - 633 
ng mL-1 
Glucagon: 85 - 
1592 ng mL-1 
Somatostatin: 
719 - 4000 ng 
mL-1 
 
Insulin: 1 nM  
Glucagon: 4 nM 
Somatostatin: 246 
nM 
50 
Fibronectin  PBS (pH 7.4) anti- 
fibronectin 
antibody 
Direct antigen 
bound to antibodies 
 
5 - 400 ng mL-1 
 
 
1.5 ng mL-1 51 
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IL-1β 
IL-6 
IFN-γ 
TNF-α 
PBS with 0.075% 
Tween 80 and 0.5% 
BSA 
Capture 
antibodies for the 
respective 
antigens 
Neutravidin and a 
gold nanoparticle 
cascade 
7 logarithms (100 
fg mL-1 - 1 μg 
mL-1  test range) 
IL-1β: 1.2 pg mL-1 
IL-6: 50 fg mL-1 
IFN-γ: 22 pg mL-1 
TNF-α:15 pg mL-1 
52 
IL-6 
IL-8 
miRNA-21 
miRNA-155 
10% normal human 
serum diluted in 
PBS (pH 7.4) 
Hairpin capture 
DNA for 
miRNAs and 
capture 
antibodies of ILs 
Fe3O4@Au 
bimetallic NPs 
tagged detection 
molecules  
IL-6: 0.02 - 100 
nM 
IL-8: 0.01 - 75 
nM 
miRNA-21: 50 
fM - 2 nM 
miRNA-155: 25 
fM - 4 nM 
IL-6: 28 pM 
IL-8: 18 pM 
miRNA-21: 502 
fM 
miRNA-155: 483 
fM 
 
This 
work 
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5.4 Conclusions 
The designed surface plasmon microarray platform offers multiplexed assaying of ILs and miRNAs 
directly from human serum samples. The combined magnetic and plasmon enhancing features of 
Fe3O4@Au NPs were useful for separating the attached detection probes easily and  amplifying the 
SPRi signal output while minimizing the non-specific signals arising from the serum matrix. These 
features improved the selectivity and sensitivity of the assay. The binding constants observed from 
the µM to nM range provide evidence for strong affinities between the analyte biomarkers and their 
receptor molecules on the designed sensor surface. Broader application of this approach to other 
proteins and miRNA biomarkers is feasible. 
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CHAPTER 6 
 
 
SUMMARY 
Development of robust and sensitive analytical approaches for the detection of biomarkers present 
in clinical matrices pave an attractive direction towards future diagnostics. As a result, clinicians 
could not only diagnose deadly diseases at a preliminary stage, but also plan suitable therapeutic 
protocols and monitor their outcomes. This dissertation discussed different nano-inspired 
electrochemical and optical analytical methodologies that were developed for small and large 
molecule biomarker measurement in view of advancing the field of biosensors. A summary of the 
objectives and associated key contributions under each chapter is presented below:    
The first chapter of this dissertation attempted to summarize and recognize the recent scientific 
contributions made on developing sensitive biosensor approaches for clinically relevant small and 
large molecule biomarker measurements. A literature review was conducted on novel 
electrochemical sensor methodologies, which combined the advancements in nanochemistry and 
the biorecognition elements such as enzymes, aptamers, antigens and antibodies. Furthermore, 
SPRi based approaches for multiplexed biomarker measurement were summarized. The 
combination of elegant nanomaterials was useful for detection signal amplification, increasing 
surface functional groups as well as highly oriented bioreceptor immobilization, and minimization 
of the non-specific interactions of molecules other than the biomarker of interest present in the 
sample matrices (e.g., serum, urine). The research field on electrochemical and SPRi biosensors is 
exponentially growing and many more novel discoveries are anticipated in the near future. 
135 
 
The second chapter reported an amperometric nano-bioelectrode design that uniquely combined 1-
pyrenebutyric acid units pi-pi stacked with carboxylated multiwalled carbon nanotubes on the 
surface of gold screen printed electrodes for covalent attachment of NAD+ dependent formaldehyde 
dehydrogenase (FDH). The designed enzyme bioelectrode offered 6 ppb formaldehyde detection 
in 10-times diluted urine with a wide dynamic range of 10 ppb to 10 ppm. Fourier transform 
infrared, Raman, and electrochemical impedance spectroscopic characterizations confirmed the 
successful design of the FDH bioelectrode. Flow injection analysis provided lower detection limit 
and greater affinity for formaldehyde (apparent KM 9.6 ± 1.2 ppm) when compared with stirred 
solution method (apparent KM 19.9 ± 4.6 ppm). Selectivity assays revealed that the bioelectrode 
was selective toward formaldehyde with a moderate cross-reactivity for acetaldehyde (~ 25%) and 
negligible cross-reactivity toward propanaldehyde, acetone, methanol, and ethanol. This 
methodology can be broadly applied for measuring other small molecule biomarkers by tuning 
marker specific enzymes.  
The next study focused on correlating picomolar affinities between surface plasmon and 
electrochemical immunoassays for the binding of serum glutamic acid decarboxylase-65 
autoantibody (GADA), a biomarker of type 1 diabetes, to its antigen GAD-65. Carboxylated (~ 
5.0%) graphene modified immunoassembly on a gold surface plasmon chip or on an 
electrochemical array provided significantly greater binding affinity, sensitivity, and lower 
detection limits than a self-assembled monolayer surface of mercaptopropionic acid (MPA). 
Estimation of the relative surface–COOH groups by covalent tagging of an electroactive 
aminoferrocene showed that the graphenyl surface displayed greater number of –COOH groups 
than the MPA surface. Additionally, the binding constant values obtained for the GADA-GAD65 
binding through real-time SPRi studies can be useful as a quality control checkpoint for 
reproducible and reliable production of large-scale biosensors for clinical bioassays. 
The fourth chapter focused on comparing detection performances of a quartz crystal microbalance 
(QCM), which is a mass sensor, with that of a surface plasmon resonance (SPR) microarray for an 
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oligonucleotide mimic of microRNA-21 biomarker. Surface immobilized capture oligonucleotide 
probe was used to hybridize with the target oligonucleotide (i.e., the microRNA-21 mimic) to 
facilitate selective detection. To obtain ultra-low femtomolar (fM) detection sensitivity, gold 
nanoparticles (50 nm) were conjugated with the target oligonucleotide. Detection limits of 28 and 
47 fM were achieved for the target oligonucleotide by the QCM and SPRi microarray, respectively. 
Additionally, sample recovery study and matrix effect analysis was performed for the target 
oligonucleotide. Although the QCM had a lower detection limit, the microarray approach offered 
better throughput for analysis of up to 16 samples. We confirmed that the designed assay was 
selective for the target oligonucleotide and did not show signals for the control oligonucleotide 
with five mismatch sites relative to the target sequence. Combination of the QCM and microarray 
methods that utilize the same assay chemistry on gold are useful for overcoming clinical sample 
matrix effects and achieving ultra-low detection of small nucleotide biomarkers with quantitative 
insights. 
In the final chapter, a surface plasmon resonance imager (SPRi) microarray employing citrate-
stabilized Fe3O4@Au core/shell nanoparticles (NPs) as the plasmon signal amplification label was 
presented. A 4-channel microfluidic system was designed to demonstrate the feasibility for 
multiplexed assaying of two serum protein markers, interleukin-6 (IL-6) and interleukin-8 (IL-8) 
by a sandwich immunoassay, and two serum microRNA markers (miRNA-21 and miRNA -155) 
by a double hybridization assay. The Fe3O4@Au (105 nm) NPs exhibited 13-times higher plasmon 
signal intensities than that of only Fe3O4 (100 nm) and 6-times greater signals than Au only NPs 
(100 nm). The detection limits achieved for the markers were in the pM to sub-pM concentrations. 
The dynamic range of detection for the proteins was from pM to nM concentration in 10% serum, 
and for the miRNAs the dynamic range was from fM to nM in 10% serum. Additionally, the 
strength of selective binding interaction between the analyte biomarkers and their surface 
bioreceptors was assessed by the Langmuir-type binding kinetics. The binding constants estimated 
for IL-6, IL-8, miRNA -21 and miRNA -155 were 2.50 (±0.17) x 107 M-1, 8.10 (±1.08) x 107 M-1, 
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7.00 (±0.76) x 108 M-1 and 7.47 (±1.10) x 108 M-1, respectively. The synergistic multiplexed 
biosensing and kinetic assessment features associated with SPRi can be useful to measure potential 
disease biomarkers and make decisions on the surface biorecognition elements on their suitability 
for the assay. 
In summary, the studies discussed in the dissertation suggest that highly sensitive, selective, and 
wide dynamic range analytical methods are of paramount significance for assaying biomarkers, 
which are typically present at very low levels in complex clinical matrices (e.g., whole blood, 
serum, saliva, tissues, and urine). The presented electrochemical biosensor methodologies offered 
highly sensitive electrochemical detection of biomarkers with minimum background effects as a 
result of the functionalization strategies employed. Also, similar nanobio-modifications can be 
adopted to expand the current electrode systems into multi-array formats for multiple biomarkers 
measurement and validation studies. With the recently growing attention on SPRi in clinical 
chemistry, this dissertation adds further significance for applications in biomarker identification 
and validation assays offering both binding insights and ‘3D’ image based assay results. 
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